

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
3 May 2001 (03.05.2001)

PCT

(10) International Publication Number  
**WO 01/30382 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 39/00, A61P 35/00**

(74) Agent: BERESKIN & PARR; 40 King Street West, 40th floor, Toronto, Ontario M5H 3Y2 (CA).

(21) International Application Number: PCT/CA00/01253

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 20 October 2000 (20.10.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/160,879 22 October 1999 (22.10.1999) US  
60/223,325 7 August 2000 (07.08.2000) US

(71) Applicant (*for all designated States except US*): AVEN-TIS PASTEUR LIMITED [CA/CA]; 1755 Steeles Avenue West, Toronto, Ontario M2R 3T4 (CA).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BERINSTEIN, Neil [CA/CA]; 31 Burton Road, Toronto, Ontario M5P 1V1 (CA). TARTAGLIA, James [US/US]; 7 Christina Drive, Schenectady, NY 12303 (US). MOINGEON, Philippe [FR/FR]; Le Chalier, F-69480 Pommiers (FR). BARBER, Brian [CA/CA]; 1428 Broadmoor Avenue, Mississauga, Ontario L5G 3T5 (CA).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 01/30382 A1

(54) Title: METHOD OF INDUCING AND/OR ENHANCING AN IMMUNE RESPONSE TO TUMOR ANTIGENS

(57) Abstract: An improved method of inducing and/or enhancing an immune response to a tumor antigen is disclosed. The method involves administering the tumor antigen, nucleic acid coding therefor, vectors and/or cells comprising said nucleic acid, or vaccines comprising the aforementioned to a lymphatic site.

JTK0044  
#9

**TITLE: Method of Inducing and/or Enhancing an Immune Response to  
Tumor Antigens**

**FIELD OF THE INVENTION**

5       The present invention relates to methods for inducing and/or enhancing immune responses to tumor antigens.

**BACKGROUND OF THE INVENTION**

Using immunological approaches to cancer therapy has been difficult as tumor cells are self-derived and therefore not as immunogenic as exogenous agents such as bacteria and viruses. As a result, the prospects of cancer immunotherapy rely upon the identification of tumor associated antigens ("TAA") which can be recognized by the immune system. Specifically, target antigens eliciting T cell-mediated responses are of critical interest. This comes from evidence that cytotoxic T lymphocytes (CTLs) can induce tumor regression both in animal models (Kast W. et al (1989) *Cell* 59:6035; Greengberg P. (1991) *Adv. Immunol.* 49:281) and in humans (Boon T. et al. (1994) *Annu. Rev. Immunol.* 12:337). To date, many tumor associated antigens have been identified. These include the antigens MAGE, BAGE, GAGE, RAGE, gp100, MART-1/Melan-A, tyrosinase, carcinoembryonic antigen (CEA) as well as many others (Horig and Kaufman (1999) *Clinical Immunology* 92:211-223). Some of these tumor associated antigens are discussed below.

The first human tumor associated antigen characterized was identified from a melanoma. This antigen (originally designated MAGE 1) was identified using CTLs isolated from an HLA A1+ melanoma patient to screen HLA A1 target cells transfected with tumor DNA (van der Bruggen P. (1991) *Science*, 254:1643; these tumor associated antigens are now designated MAGE-A1, MAGE-A2, etc.). Interestingly, MAGE 1 was found to

belong to a family of at least 12 closely related genes located on the X chromosome (de Plaen, E. et al. (1994) *Immunogenetics* 40:360). The nucleic acid sequence of the 11 additional MAGE genes share 65-85% identity with that of MAGE-1 (de Smet, C. et al. (1994) *Immunogenetics* 39:121). Both MAGE 1 and 3 are present in normal tissues, but expressed only in the testis (de Plaen, E. et al. (1994) *Supra*; de Smet, C. et al. (1994) *Supra*; Takahashi, K. et al. (1995) *Cancer Res.* 55:3478; Chyomey, P. et al. (1995) *Immunogenetics* 43:97). These initial results have subsequently been extended with the identification of new gene families (i.e. RAGE, BAGE, GAGE), all of which are typically not expressed in normal tissues (except testis) but expressed in a variety of tumor types.

Human carcinoembryonic antigen (CEA) is a 180 kD glycoprotein expressed on the majority of colon, rectal, stomach and pancreatic tumors (Muaro et al. (1985) *Cancer Res.* 45:5769), some 50% of breast carcinomas (Steward et al. (1974) *Cancer* 33:1246) and 70% of lung carcinomas (Vincent, R.G. and Chu, T.M. (1978) *J. Thor. Cardiovas. Surg.* 66:320). CEA was first described as a cancer specific fetal antigen in adenocarcinoma of the human digestive tract in 1965 (Gold, P. and Freeman, S.O. (1965) *Exp. Med.* 121:439). Since that time, CEA has been characterized as a cell surface antigen produced in excess in nearly all solid tumors of the human gastrointestinal tract. The gene for the human CEA protein has been cloned (Oikawa et al (1987) *Biochim. Biophys. Res.* 142:511-518; European Application No. EP 0346710). CEA is also expressed in fetal gut tissue and to a lesser extent on normal colon epithelium. The immunogenicity of CEA has been ambiguous, with several studies reporting the presence of anti-CEA antibodies in patients (Gold et al. (1973) *Nature New Biology* 239:60; Pompecki, R. (1980) *Eur. J. Cancer* 16:973; Ura et al. (1985) *Cancer Lett.* 25:283; Fuchs et al. (1988) *Cancer Immunol. Immunother.* 26:180)

while other studies have not (LoGerfo et al. (1972) *Int. J. Cancer* 9:344; MacSween, J.M. (1975) *Int. J. Cancer* 15:246; Chester K.A. and Begent, H.J. (1984) *Clin. Exp. Immunol.* 58:685).

Gp100 is normally found in melanosomes and expressed in melanocytes, retinal cells, and other neural crest derivatives. The function of gp100 is currently unknown. By mass spectrometry, three immunodominant HLA-A2 binding gp100 epitopes have been identified: g9-154 (amino acids 154-162), g9-209 (amino acids 209-217); and g9-280 (amino acids 280-288). Notably, two of these epitopes (as peptides) have been synthetically altered so as to induce a more vigorous immune response in the original T cell clone: the threonine at position 2 in gp-209 was changed to a methionine, and the alanine residue at position 9 in gp-280 was changed to a valine. These changes increase the binding affinity of the epitope-peptides to the HLA-A2 molecule without changing the intrinsic natural epitopes recognized by the T cell receptor (TCR). Rosenberg and colleagues (NIH) have already successfully immunized melanoma patients with one of these modified peptides and have reported achieving objective clinical responses in some patients.

Despite significant advances that have been made with respect to immunological approaches to cancer treatment, there is still a need in the art to improve cancer immunotherapies.

#### **SUMMARY OF THE INVENTION**

The present invention relates to improved methods for inducing and/or enhancing an immune response to a tumor antigen.

The present inventors have found that administering the tumor antigen or nucleic acid coding therefor directly into a lymphatic site (such as a lymph node) induces and/or significantly enhances the immune response to the tumor antigen and/or breaks tolerance to the tumor antigen, both

which have been a major challenge in previous methods of cancer immunotherapy.

Accordingly, one aspect the present invention provides a method for inducing and/or enhancing an immune response in an animal to a tumor antigen comprising administering an effective amount of a tumor antigen, nucleic acid coding therefor, vector or cell comprising said nucleic acid, or vaccine comprising the aforementioned to a lymphatic site in the animal.

In another aspect, the present invention provides a method for breaking immune tolerance to a tumor antigen in an animal comprising administering an effective amount of a tumor antigen, nucleic acid coding therefor, vector or cell comprising said nucleic acid, or vaccine comprising the aforementioned to a lymphatic site in the animal.

Other features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the invention are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

## 20 **BRIEF DESCRIPTION OF THE DRAWINGS**

The invention will now be described in relation to the drawings in which:

Figure 1 is a bar graph showing the results of an IFN- $\gamma$ -ELISPOT analysis of an animal receiving an intranodal injection of the tumor antigen.

Figure 2 is a bar graph showing the results of an IFN- $\gamma$ -ELISPOT analysis of an animal receiving an intranodal injection of the tumor antigen.

Figure 3 is a bar graph showing the results of an IFN- $\gamma$ -ELISPOT analysis of an animal receiving a subcutaneous injection of the tumor antigen.

Figure 4 is a bar graph showing the results of an IFN- $\gamma$ -ELISPOT analysis of an animal receiving a subcutaneous injection of the tumor antigen.

Figure 5 is a graph showing the antibody response after a regiment  
5 of intranodal (group 2) and subcutaneous (group 3) administration of ALVAC-modified gp100/modified gp100 peptide immunogens.

Figure 6 is the nucleic acid sequence of a modified gp100M cDNA (SEQ.ID.NO.:109).

Figure 7 is the deduced amino acid sequence of the modified  
10 gp100M protein (SEQ.ID.NO.:110).

Figure 8 is the nucleic acid and amino acid sequence of a modified CEA (SEQ.ID.NOS.: 111 and 112).

#### **DETAILED DESCRIPTION OF THE INVENTION**

As hereinbefore mentioned, the present invention relates to an improved method for inducing and/or enhancing the immune response to a tumor antigen. Accordingly, the present invention provides a method for inducing and/or enhancing an immune response in an animal to a tumor antigen comprising administering an effective amount of a tumor antigen, a nucleic acid sequence encoding a tumor antigen, a vector or cell comprising the nucleic acid sequence, or a vaccine comprising the tumor antigen, the nucleic acid sequence encoding the tumor antigen, or a vector comprising the nucleic acid sequence encoding the tumor antigen to a lymphatic site in the animal.

The term "inducing and/or enhancing an immune response" means  
25 that the method evokes and/or enhances any response of the animal's immune system.

"Immune response" is defined as any response of the immune system, for example, of either a cell-mediated (i.e. cytotoxic T-lymphocyte

mediated) or humoral (i.e. antibody mediated) nature. These immune responses can be assessed by a number of *in vivo* or *in vitro* assays well known to one skilled in the art including, but not limited to, antibody assays (for example ELISA assays) antigen specific cytotoxicity assays, production 5 of cytokines (for example ELISPOT assays), regression of tumors expressing the tumor antigens, inhibition of cancer cells expressing the tumor antigens, etc..

The term "lymphatic site" means a site in the body that is associated with the lymphatic system including lymphatic organs, tissues, cells, nodes 10 or glands such as spleen, thymus, tonsils, Peyer's patches, bone marrow, lymphocytes, thoracic duct as well as all of the lymph nodes of the body.

The term "animal" as used herein includes all members of the animal kingdom and is preferably human.

The term "effective amount" as used herein means an amount 15 effective, at dosages and for periods of time necessary to achieve the desired results.

The term "tumor antigen" as used herein includes both tumor associated antigens (TAAs) and tumor specific antigens (TSAs). A tumor associated antigen means an antigen that is expressed on the surface of a 20 tumor cell in higher amounts than is observed on normal cells or an antigen that is expressed on normal cells during fetal development. A tumor specific antigen is an antigen that is unique to tumor cells and is not expressed on normal cells. The term tumor antigen includes TAAs or TSAs that have been already identified and those that have yet to be identified and 25 includes fragments, epitopes and any and all modifications to the tumor antigens.

The tumor associated antigen can be any tumor associated antigen including, but not limited to, gp100 (Kawakami et al., *J. Immunol.* 154:3961-

3968 (1995); Cox et al., *Science*, 264:716-719 (1994)), MART - 1/Melan A (Kawakami et al., *J. Exp. Med.*, 180:347-352 (1994); Castelli et al., *J. Exp. Med.*, 181:363-368 (1995)), gp75 (TRP-1) (Wang et al., *J. Exp. Med.*, 186:1131-1140 (1996)), and Tyrosinase (Wolfel et al., *Eur. J. Immunol.*, 5 24:759-764 (1994); Topalian et at., *J. Exp. Med.*, 183:1965-1971 (1996)) melanoma proteoglycan (Hellstrom et al., *J. Immunol.*, 130:1467-1 (1983); Ross et al., *Arch. Biochem Biophys.*, 225:370-383 (1983)); tumor-specific, widely shared antigens, for example: antigens of MAGE family, for example, MAGE-1, 2,3,4,6, and 12 (Van der Bruggen et al., *Science*, 10 254:1643-1647 (1991 )); Rogner et al., *Genomics*, 29:729-731 (1995)), antigens of BAGE family (Boel et al., *Immunity*, 2:167-175 (1995)), antigens of GAGE family, for example, GAGE-1,2 (Van den Eynde et al., *J. Exp. Med.*, 182:689-698 (1995)), antigens of RAGE family, for example, RAGE-1 (Gaugler et at., *Immunogenetics*, 44:323-330 (1996)), N- 15 acetylglucosaminyltransferase-V (Guilloux et at., *J. Exp. Med.*, 183:1173-1183 (1996)), and p15 (Robbins et al., *J. Immunol.* 154:5944-5950 (1995)); tumor specific mutated antigens; mutated  $\beta$ -catenin (Robbins et al., *J. Exp. Med.*, 183:1185-1192 (1996)), mutated MUM-1 (Coulie et al., *Proc. Natl. Acad. Sci. USA*, 92:7976-7980 (1995)), and mutated cyclin dependent 20 kinases-4 (CDK4) (Wolfel et al., *Science*, 269:1281-1284 (1995)); mutated oncogene products: p21 ras (Fossum et at., *Int. J. Cancer*, 56:40-45 (1994)), BCR-abl (Bocchia et al., *Blood*, 85:2680-2684 (1995)), p53 (Theobald et al., *Proc. Natl. Acad. Sci. USA*, 92:11993-11997 (1995)), and p185 HER2/neu (Fisk et al., *J. Exp. Med.*, 181:2109-2117 (1995)); Peoples et al., *Proc. Natl. Acad. Sci., USA*, 92:432-436 (1995)); mutated epidermal growth factor receptor (EGFR) (Fujimoto et al., *Eur. J. Gynecol. Oncol.*, 16:40-47 (1995)); Harris et al., *Breast Cancer Res. Treat.*, 29:1-2 (1994)); carcinoembryonic 25 antigens (CEA) (Kwong et al., *J. Natl. Cancer Inst.*, 85:982-990 (1995));

carcinoma associated mutated mucins, for example, MUC-1 gene products (Jerome et al., *J. Immunol.*, 151:1654-1662 (1993), Ioannides et al., *J. Immunol.*, 151:3693-3703 (1993), Takahashi et al., *J. Immunol.*, 153:2102-2109 (1994)); EBNA gene products of EBV, for example, EBNA-1 gene product (Rickinson et al., *Cancer Surveys*, 13:53-80 (1992)); E7, E6 proteins of human papillomavirus (Ressing et al., *J. Immunol.*, 154:5934-5943 (1995)); prostate specific antigens (PSA) (Xue et al., *The Prostate*, 30:73-78 (1997)); prostate specific membrane antigen (PSMA) (Israeli, et al., *Cancer Res.*, 54:1807-1811 (1994)); PCTA-1 (Sue et al., *Proc. Natl. Acad. Sci. USA*, 10 93:7252-7257 (1996)); idiotypic epitopes or antigens, for example, immunoglobulin idiotypes or T cell receptor idiotypes, (Chen et al., *J. Immunol.*, 153:4775-4787 (1994); Syrengelas et al., *Nat. Med.*, 2:1038-1040 (1996)); KSA (US Patent # 5348887); NY-ESO-1 (WO 98/14464).

Also included are modified tumor antigens and/or epitope/peptides derived therefrom (both unmodified and modified). Examples include, but are not limited to, modified and unmodified epitope/peptides derived from gp100 (WO 98/02598; WO 95/29193; WO 97/34613; WO 98/33810; CEA (WO 99/19478; S. Zaremba et al. (1997) *Cancer Research* 57:4570-7; K.T. Tsang et al. (1995) *J. Int. Cancer Inst.* 87:982-90); MART-1 (WO 98/58951, 15 WO 98/02538; D. Valmeri et al. (2000) *J. Immunol.* 164:1125-31); p53 (M. Eura et al. (2000) *Clinical Cancer Research* 6:979-86); TRP-1 and TRP-2 (WO 97/29195); tyrosinase (WO 96/21734; WO 97/11669; WO 97/34613; WO 98/33810; WO 95/23234; WO 97/26535); KSA (WO 97/15597); PSA (WO 96/40754); NY-ESO 1 (WO 99/18206); HER2/neu (US Patent #5869445); 20 MAGE family related (L. Heidecker et al. (2000) *J. Immunol.* 164:6041-5; WO 95/04542; WO 95/25530; WO 95/25739; WO 96/26214; WO 97/31017; WO 98/10780).

In a preferred embodiment, the tumor-associated antigen is gp100, a modified gp100 or a fragment thereof. In particular, the inventors have prepared a modified gp100 peptide termed gp100M which has the nucleic acid sequence shown in Figure 6 (SEQ.ID.NO.:109) and the deduced amino acid sequence shown in Figure 7 (SEQ.ID.NO.:110). The inventors have shown that the intranodal injection of a recombinant avipox virus comprising a nucleic acid coding for fragments of the modified gp100 (comprising modified epitopes 209(2M) (IMDQVPPFSY, SEQ.ID.NO.:1) and 290(9V) (YLEPGPVTV, SEQ.ID.NO.:2)) followed by modified epitope/peptide boosts induced both a humoral and cell mediated response that was several times higher than when the same antigens were administered subcutaneously.

10 The experimental details and results are discussed in Example 1.

In another embodiment, the tumor-associated antigen is carcinoembryonic antigen (CEA), a modified CEA or a fragment thereof. The nucleic acid sequence of a modified CEA antigen is shown in Figure 8 and SEQ.ID.NO.:111. The corresponding amino acid sequence is shown in Figure 8 and SEQ.ID.NO.:112. Preferably, the modified CEA antigen comprises the sequence YLSGADLNL, SEQ.ID.NO.:113.

Additional embodiments of the invention encompass nucleic acid sequences comprising sequences encoding the tumor antigens and fragments or modified forms thereof as hereinbefore described. The term "nucleic acid sequence" refers to a sequence of nucleotide or nucleoside monomers consisting of naturally occurring bases, sugars and intersugar (backbone) linkages. The term also includes modified or substituted sequences comprising non-naturally occurring monomers or portions thereof, which function similarly. The nucleic acid sequences of the present invention may be ribonucleic (RNA) or deoxyribonucleic acids (DNA) and may contain naturally occurring bases including adenine, guanine, cytosine, thymidine and uracil. The sequences may also contain modified bases such as xanthine, hypoxanthine, 2-aminoadenine, 6-methyl, 2-propyl, and

10  
other alkyl adenines, 5-halo uracil, 5-halo cytosine, 6-aza uracil, 6-aza cytosine and 6-aza thymine, pseudo uracil, 4-thiouracil, 8-halo adenine, 8-amino adenine, 8-thiol adenine, 8-thio-alkyl adenines, 8-hydroxyl adenine and other 8-substituted adenines, 8-halo guanines, 8-amino guanine, 8-thiol guanine, 8-thioalkyl guanines, 8-hydroxyl guanine and other 8-substituted guanines, other aza and deaza uracils, thymidines, cytosines, adenines, or guanines, 5-trifluoromethyl uracil and 5-trifluoro cytosine.

The nucleic acid sequences encoding the tumor antigens of the invention include, but are not limited to, viral nucleic acid(s), plasmid(s),  
10 bacterial DNA, naked/free DNA and RNA. The nucleic acids encompass both single and double stranded forms. As such, these nucleic acids comprise the relevant base sequences coding for the aforementioned tumor antigens. For purposes of definitiveness, the "relevant base sequences coding for the aforementioned polypeptides" further encompass  
15 complementary nucleic acid sequences. As such, embodiments of the invention encompass nucleic acid sequences *per se* encoding for the aforementioned tumor antigens, or recombinant nucleic acids into which has been inserted said nucleic acids coding for tumor antigens (as described below).

20 Bacterial DNA useful in recombinant nucleic acid embodiments of the invention are known to those of ordinary skill in the art. Sources of bacterial DNA include, for example, *Shigella*, *Salmonella*, *Vibrio cholerae*, *Lactobacillus*, *Bacille Calmette Guérin* (BCG), and *Streptococcus*. In bacterial DNA embodiments of the invention, nucleic acid of the invention  
25 may be inserted into the bacterial genome, can remain in a free state, or be carried on a plasmid.

30 Viral recombinant nucleic acid embodiments of the invention may be derived from a poxvirus or other virus such as adenovirus or alphavirus. Preferably the viral nucleic acid is incapable of integration in recipient animal cells. The elements for expression from said nucleic acid may include a promoter suitable for expression in recipient animal cells.

11

Specific vial recombinant nucleic acid embodiments of the invention encompass (but are not limited to) poxviral, alphaviral, and adenoviral nucleic acid. Poxviral nucleic acid may be selected from the group consisting of avipox, orthopox, and suipox nucleic acid. Particular 5 embodiments encompass poxviral nucleic acid selected from vaccinia, fowlpox, canary pox and swinepox; specific examples include TROVAC, NYVAC, ALVAC, MVA, Wyeth and Poxvac-TC (described in more detail below).

It is further contemplated that recombinant nucleic acids of this 10 invention may further comprise nucleic acid sequences encoding at least one member chosen from the group consisting of cytokines, lymphokines, and co-stimulatory molecules. Examples include (but are not limited to) interleukin 2, interleukin 12, interleukin 6, interferon gamma, tumor necrosis factor Alpha, GM-CSF, B7.1, B7.2, ICAM-1, LFA-3, and Cd72.

15 Standard techniques of molecular biology for preparing and purifying nucleic acids well known to those skilled in the art can be used in the preparation of the recombinant nucleic acid aspects of the invention (for example, as taught in *Current Protocols in Molecular Biology*, F.M. Ausubel et al. (Eds.), John Wiley and Sons, Inc, N.Y., U.S.A. (1998), Chpts. 1, 2 and 4; 20 *Molecular Cloning: A Laboratory Manual* (2<sup>nd</sup> Ed.), J. Sambrook, E.F. Fritsch and T. Maniatis (Eds.), Cold Spring Harbor Laboratory Press, N.Y., U.S.A. (1989), Chpts. 1, 2, 3 and 7).

Aspects of this invention further encompass vectors comprising the aforementioned nucleic acids. In certain embodiments, said vectors may be 25 recombinant viruses or bacteria (as described below).

Adenovirus vectors and methods for their construction have been described (e.g. U.S. Patent Nos. 5994132, 5932210, 6057158 and Published PCT Applications WO 9817783, WO 9744475, WO 9961034, WO 9950292, WO 9927101, WO 9720575, WO 9640955, WO 9630534-all of 30 which are herein incorporated by reference). Alphavirus vectors have also been described in the art and can be used in embodiments of this invention (e.g. U.S. Patent Nos. 5792462, 5739026, 5843723, 5789245, and

12

Published PCT Applications WO 9210578, WO 9527044, WO 9531565, WO 9815636-all of which are herein incorporated by reference), as have lentivirus vectors (e.g. U.S. Patent Nos. 6013516, 5994136 and Published PCT Applications WO 9817816, WO 9712622, WO 9817815, WO 9839463,

5 WO 9846083, WO 9915641, WO 9919501, WO 9930742, WO 9931251, WO 9851810, WO 0000600-all of which are herein incorporated by reference). Poxvirus vectors that can be used include, for example, avipox, orthopox or suipox poxvirus (as described in U.S. Patent Nos. 5364773, 4603112, 5762938, 5378457, 5494807, 5505941, 5756103, 5833975 and 5990091-

10 all of which are herein incorporated by reference). Poxvirus vectors comprising a nucleic acid coding for a tumor antigen can be obtained by homologous recombination as is known to one skilled in the art. As such, the nucleic acid coding for the tumor antigen is inserted into the viral genome under appropriate conditions for expression in mammalian cells

15 (as described below).

In one embodiment of the invention the poxvirus vector is ALVAC (1) or ALVAC (2) (both of which have been derived from canarypox virus). ALVAC (1) (or ALVAC (2)) does not productively replicate in non-avian hosts, a characteristic thought to improve its safety profile. ALVAC (1) is an attenuated canarypox virus-based vector that was a plaque-cloned derivative of the licensed canarypox vaccine, Kanapox (Tartaglia et al. (1992) *Virology* 188:217; U.S. Patent Nos. 5505941, 5756103 and 5833975-all of which are incorporated herein by reference). ALVAC (1) has some general properties which are the same as some general properties of Kanapox. ALVAC-based recombinant viruses expressing extrinsic immunogens have also been demonstrated efficacious as vaccine vectors (Tartaglia et al., In AIDS Research Reviews (vol. 3) Koff W., Wong-Staal F. and Kenedy R.C. (eds.), Marcel Dekker NY, pp. 361-378 (1993a); Tartaglia, J. et al. (1993b) *J. Virol.* 67:2370). For instance, mice immunized with an ALVAC (1) recombinant expressing the rabies virus glycoprotein were protected from lethal challenge with rabies virus (Tartaglia, J. et al., (1992) *supra*) demonstrating the potential for ALVAC (1) as a vaccine vector. ALVAC-based recombinants

have also proven efficacious in dogs challenged with canine distemper virus (Taylor, J. et al. (1992) *Virology* 187:321) and rabies virus (Perkus, M.E. et al., In Combined Vaccines and Simultaneous Administration: Current Issues and Perspective, Annals of the New York Academy of Sciences 5 (1994)), in cats challenged with feline leukemia virus (Tartaglia, J. et al., (1993b) *supra*), and in horses challenged with equine influenza virus (Taylor, J. et al., In Proceedings of the Third International Symposium on Avian Influenza, Univ. of Wisconsin-Madison, Madison, Wisconsin, pp. 331-335 (1993)).

10 ALVAC (2) is a second-generation ALVAC vector in which vaccinia transcription elements E3L and K3L have been inserted within the C6 locus (U.S. Patent No. 5990091, incorporated herein by reference). The E3L encodes a protein capable of specifically binding to dsRNA. The K3L ORF has significant homology to E1F-2. Within ALVAC (2) the E3L gene is under 15 the transcriptional control of its natural promoter, whereas K3L has been placed under the control of the early/late vaccine H6 promoter. The E3L and K3L genes act to inhibit PKR activity in cells infected with ALVAC (2), allowing enhancement of the level and persistence of foreign gene expression.

20 Additional viral vectors encompass natural host-restricted poxviruses. Fowlpox virus (FPV) is the prototypic virus of the Avipox genus of the Poxvirus family. Replication of avipox viruses is limited to avian species (Matthews, R.E.F. (1982) *Intervirology* 17:42) and there are no reports in the literature of avipox virus causing a productive infection in any non-avian species 25 including man. This host restriction provides an inherent safety barrier to transmission of the virus to other species and makes use of avipox virus based vectors in veterinary and human applications an attractive proposition.

FPV has been used advantageously as a vector expressing 30 immunogens from poultry pathogens. The hemagglutinin protein of a virulent avian influenza virus was expressed in an FPV recombinant. After inoculation of the recombinant into chickens and turkeys, an immune

14

- response was induced which was protective against either a homologous or a heterologous virulent influenza virus challenge (Taylor, J. et al. (1988) *Vaccine* 6: 504). FPV recombinants expressing the surface glycoproteins of Newcastle Disease Virus have also been developed (Taylor, J. et al. (1990) 5 *J. Virol.* 64:1441; Edbauer, C. et al. (1990) *Virology* 179:901; U.S. Patent No. 5766599-incorporated herein by reference).

A highly attenuated strain of vaccinia, designated MVA, has also been used as a vector for poxvirus-based vaccines. Use of MVA is described in U.S. Patent No. 5,185,146.

- 10 Other attenuated poxvirus vectors have been prepared via genetic modification to wild type strains of vaccinia. The NYVAC vector, for example, is derived by deletion of specific virulence and host-range genes from the Copenhagen strain of vaccinia (Tartaglia, J. et al. (1992), *supra*; U.S. Patent Nos. 5364773 and 5494807-incorporated herein by reference) and has  
15 proven useful as a recombinant vector in eliciting a protective immune response against expressed foreign antigens.

- Recombinant viruses can be constructed by processes known to those skilled in the art (for example, as previously described for vaccinia and avipox viruses; U.S. Patent Nos. 4769330; 4722848; 4603112; 5110587; 20 and 5174993-all of which are incorporated herein by reference).

- In further embodiments of the invention, live and/or attenuated bacteria may also be used as vectors. For example, non-toxicogenic *Vibrio cholerae* mutant strains may be useful as bacterial vectors in embodiments of this invention; as described in US Patent No. 4,882,278 (disclosing a 25 strain in which a substantial amount of the coding sequence of each of the two *ctxA* alleles has been deleted so that no functional cholera toxin is produced), WO 92/11354 (strain in which the *irgA* locus is inactivated by mutation; this mutation can be combined in a single strain with *ctxA* mutations), and WO 94/1533 (deletion mutant lacking functional *ctxA* and 30 *attRS1* DNA sequences). These strains can be genetically engineered to express heterologous antigens, as described in WO 94/19482. (All of the

aforementioned issued patent/patent applications are incorporated herein by reference.)

Attenuated *Salmonella typhimurium* strains, genetically engineered for recombinant expression of heterologous antigens and their use as oral  
5 immunogens are described, for example, in WO 92/11361.

As noted, those skilled in the art will readily recognize that other bacterial strains useful as bacterial vectors in embodiments of this invention include (but are not limited to) *Shigella flexneri*, *Streptococcus gordonii*, and Bacille Calmette Guerin (as described in WO 88/6626, WO 90/0594, WO  
10 91/13157, WO 92/1796, and WO 92/21376; all of which are incorporated herein by reference). In bacterial vector embodiments of this invention, a nucleic acid coding for a tumor antigen may be inserted into the bacterial genome, can remain in a free state, or be carried on a plasmid.

It is further contemplated that the invention encompasses vectors  
15 which comprise nucleic acids coding for at least one member from the group consisting of cytokines, lymphokines and immunostimulatory molecules. Said nucleic acid sequences can be contiguous with sequences coding for the tumor antigen or encoded on distinct nucleic acids.

20 Cells comprising the aforementioned tumor antigens, nucleic acids coding therefor, and/or vectors encompass further embodiments of the invention. These cells encompass any potential cell into which the aforementioned tumor antigen, nucleic acid, and/or vector might be introduced and/or transfected and/or infected (for example, bacteria, COS  
25 cells, Vero cells, chick embryo fibroblasts, tumor cells, antigen presenting cells, dendritic cells, etc.). The choice of process for the introduction and/or transfection and/or infection into cells is dependant upon the intrinsic nature of the introduced agent (i.e. free DNA, plasmid, recombinant virus), as will be known to one skilled in the art (for example, as taught in *Current  
30 Protocols in Molecular Biology*, F.M. Ausubel et al. (Eds.), John Wiley and Sons, Inc., N.Y., U.S.A. (1998), Chpt. 9; *Molecular Cloning: A Laboratory*

16

*Manual (2nd Ed.)*, J. Sambrook, E.F. Fritsch and T. Maniatis (Eds.), Cold Spring Harbor Laboratory Press, N.Y., U.S.A. (1989), Chpts. 1, 2, 3 and 16).

Further embodiments of the invention encompass vaccines comprising the tumor antigens and/or nucleic acids coding therefor and/or  
5 vectors and/or cells previously described.

The vaccine of the invention comprising the tumor antigen may be a multivalent vaccine and additionally contain several peptides, epitopes or fragments of a particular tumor antigen or contain peptides related to other tumor antigens and/or infectious agents in a prophylactically or  
10 therapeutically effective manner. Multivalent vaccines against cancers may contain a number of individual TAA's, or immunogenic fragments thereof, alone or in combinations which are effective to modulate an immune response to cancer.

A vaccine of the invention may contain a nucleic acid molecule  
15 encoding a tumor antigen of the invention. Such vaccines are referred to as nucleic acid vaccines but are also termed genetic vaccines, polynucleotide vaccines or DNA vaccines, all of which are within the scope of the present invention. In such an embodiment, the tumor antigen is produced *in vivo* in the host animal. Additional embodiments if the invention encompass  
20 vectors (i.e. bacteria, recombinant viruses) comprising the aforementioned nucleic acids.

The present invention also contemplates mixtures of the tumor antigens, nucleic acids coding therefor, vectors comprising said nucleic acids, cells and/or vaccines comprising the aforementioned, and at least  
25 one member selected from the group consisting of cytokines, lymphokines, immunostimulatory molecules, and nucleic acids coding therefor. Additional embodiments of this invention further encompass pharmaceutical compositions comprising the aforementioned tumor antigens, nucleic acids coding therefor, vectors, cells, vaccines or mixtures  
30 for administration to subjects in a biologically compatible form suitable for administration *in vivo*. By "biologically compatible form suitable for administration *in vivo*" is meant a form of the substance to be administered

in which any toxic effects are outweighed by the therapeutic effects. Administration of a therapeutically active amount of the pharmaceutical compositions of the present invention, or an "effective amount", is defined as an amount effective at dosages and for periods of time, necessary to  
5 achieve the desired result of eliciting an immune response in an animal. A therapeutically effective amount of a substance may vary according to factors such as the disease state/health, age, sex, and weight of the recipient, and the inherent ability of the particular tumor antigen, nucleic acid coding therefor, vector, cell, or vaccine to elicit a desired immune response.  
10 Dosage regima may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily, or at periodic intervals, and/or the dose may be proportionally reduced as indicated by the exigencies of circumstances.

The pharmaceutical compositions described herein can be prepared  
15 by *per se* known methods for the preparation of pharmaceutically acceptable compositions which can be administered to animals such that an effective quantity of the active substance (i.e. tumor antigen, nucleic acid, recombinant virus, vaccine) is combined in a mixture with a pharmaceutically acceptable vehicle. Suitable vehicles are described, for  
20 example, in "Handbook of Pharmaceutical Additives" (compiled by Michael and Irene Ash, Gower Publishing Limited, Aldershot, England (1995)). On this basis, the compositions include, albeit not exclusively, solutions of the substances in association with one or more pharmaceutically acceptable vehicles or diluents, and may be contained in buffered solutions with a  
25 suitable pH and/or be iso-osmotic with physiological fluids. In this regard, reference can be made to U.S. Patent No. 5,843,456. These compositions may further comprise an adjuvant (as described below).

Further embodiments of the invention encompass methods of inhibiting a tumor antigen expressing cancer cell in a patient comprising  
30 administering to said patient an effective amount of a tumor antigen, nucleic acid coding therefor, vector, cell, or vaccine of the invention. Patients with solid tumors expressing tumor antigens include (but are not limited to)

18

those suffering from colon cancer, lung cancer, pancreas cancer, endometrial cancer, breast cancer, thyroid cancer, melanoma, oral cancer, laryngeal cancer, seminoma, hepatocellular cancer, bile duct cancer, squamous cell carcinoma, and prostate cancer. As such, methods of 5 treating patients with cancer *per se* encompassing the aforementioned methods of inducing an immune response and/or inhibiting a tumor antigen expressing cell are contemplated aspects/embodiments of the invention.

As mentioned previously, an animal may be immunized with a tumor antigen, nucleic acid coding therefore, vector, cell or vaccine of the invention 10 by administering the aforementioned to a lymphatic site. The administration can be achieved in a single dose or repeated at intervals. The appropriate dosage is dependant on various parameters understood by the skilled artisans, such as the immunogen itself (i.e. polypeptide vs. nucleic acid (and more specifically type thereof)), the route of administration and the 15 condition of the animal to be vaccinated (weight, age and the like).

As previously noted, nucleic acids (in particular plasmids and/or free/naked DNA and/or RNA coding for the tumor antigen of the invention) can be administered to an animal for purposes of inducing/elicitng an immune response (for example, US Patent No. 5589466; McDonnell and 20 Askari, *NEJM* 334:42-45 (1996); Kowalczyk and Ertl, *Cell Mol. Life Sci.* 55:751-770 (1999)). Typically, this nucleic acid is a form that is unable to replicate in the target animal's cell and unable to integrate in said animal's genome. The DNA/RNA molecule encoding the tumor antigen is also typically placed under the control of a promoter suitable for expression in the 25 animal's cell. The promoter can function ubiquitously or tissue-specifically. Examples of non-tissue specific promoters include the early Cytomegalovirus (CMV) promoter (described in U.S. Patent No. 4,168,062) and the Rous Sarcoma Virus promoter. The desmin promoter is tissue-specific and drives expression in muscle cells. More generally, useful 30 vectors have been described (i.e., WO 94/21797).

For administration of nucleic acids coding for a tumor antigen, said nucleic acid can encode a precursor or mature form of the

polypeptide/protein. When it encodes a precursor form, the precursor form can be homologous or heterologous. In the latter case, a eucaryotic leader sequence can be used, such as the leader sequence of the tissue-type plasminogen factor (tPA).

5 For use as an immunogen, a nucleic acid of the invention can be formulated according to various methods known to a skilled artisan. First, a nucleic acid can be used in a naked/free form, free of any delivery vehicles (such as anionic liposomes, cationic lipids, microparticles, (e.g., gold microparticles), precipitating agents (e.g., calcium phosphate) or any other  
10 transfection-facilitating agent. In this case the nucleic acid can be simply diluted in a physiologically acceptable solution (such as sterile saline or sterile buffered saline) with or without a carrier. When present, the carrier preferably is isotonic, hypotonic, or weakly hypertonic, and has a relatively low ionic strength (such as provided by a sucrose solution (e.g., a solution  
15 containing 20% sucrose)).

Alternatively, a nucleic acid can be associated with agents that assist in cellular uptake. It can be, i.e., (i) complemented with a chemical agent that modifies the cellular permeability (such as bupivacaine; see, for example, WO 94/16737), (ii) encapsulated into liposomes, or (iii)  
20 associated with cationic lipids or silica, gold, or tungsten microparticles.

Cationic lipids are well known in the art and are commonly used for gene delivery. Such lipids include Lipofectin (also known as DOTMA (N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride), DOTAP (1,2-bis(oleyloxy)-3-(trimethylammonio) propane). DDAB (dimethyldioctadecyl-  
25 ammonium bromide), DOGS (dioctadecylamidoglycyl spermine) and cholesterol derivatives such as DC-Chol (3 beta-(N-(N',N'-dimethyl aminomethane)-carbamoyl) cholesterol). A description of these cationic lipids can be found in EP 187702, WO 90/11092, U.S. Patent No. 5283185,  
WO 91/15501, WO 95/26356, and U.S. Patent No. 5527928. Cationic lipids  
30 for gene delivery are preferably used in association with a neutral lipid such as DOPE (dioleyl phosphatidylethanolamine) as, for example, described in WO 90/11092.

20

Other transfection-facilitating compounds can be added to a formulation containing cationic liposomes. A number of them are described in, for example, WO 93/18759, WO 93/19768, WO 94/25608, and WO 95/2397. They include, for example, spermine derivatives useful for 5 facilitating the transport of DNA through the nuclear membrane (see, for example, WO 93/18759) and membrane-permeabilizing compounds such as GALA, Gramicidine S, and cationic bile salts (see, for example, WO 93/19768).

Gold or tungsten microparticles can also be used for nucleic acid 10 delivery (as described in WO 91/359 and WO 93/17706). In this case, the microparticle-coated polynucleotides can be injected via intradermal or intraepidermal routes using a needleless injection device ("gene gun"; such as those described, for example, in U.S. Patent No. 4,945,050, U.S. Patent No. 5,015,580, and WO 94/24263).

15 Anionic and neutral liposomes are also well-known in the art (see, for example, Liposomes: A Practical Approach, RPC New Ed, IRL Press (1990), for a detailed description of methods for making liposomes) and are useful for delivering a large range of products, including nucleic acids.

Particular embodiments of the aforementioned methods (i.e. to 20 induce/elicit immune responses) encompass prime-boost protocols for the administration of immunogens of the invention. More specifically, these protocols encompass (but are not limited to) a "priming" step with a particular/distinct form of immunogen (i.e. nucleic acid (for example, plasmid, bacterial/viral/free or naked)) coding for tumor antigen, or vector 25 (i.e. recombinant virus, bacteria) comprising said nucleic acid) followed by at least one "boosting" step encompassing the administration of an alternate (i.e. distinct from that used to "prime") form of the tumor antigen (i.e. protein or fragment thereof (for example, epitope/peptide), nucleic acid coding for the tumor antigen (or fragment thereof), or vector comprising said 30 nucleic acid). Examples of "prime-boost" methodologies are known to those skilled in the art (as taught, for example, in PCT published applications WO 98/58956, WO 98/56919, WO 97/39771). One advantage

21

of said protocols is the potential to circumvent the problem of generating neutralizing immune responses to vectors *per se* (i.e. recombinant viruses) wherein is inserted/incorporated nucleic acids encoding the immunogen or fragments thereof (see for example, R.M. Conry et al. (2000) *Clin. Cancer Res.* 6:34-41).

As is well known to those of ordinary skill in the art, the ability of an immunogen to induce/elicit an immune response can be improved if, regardless of administration formulation (i.e. recombinant virus, nucleic acid, polypeptide), said immunogen is co-administered with an adjuvant.

10 Adjuvants are described and discussed in "Vaccine Design-the Subunit and Adjuvant Approach" (edited by Powell and Newman, Plenum Press, New York, U.S.A., pp. 61-79 and 141-228 (1995)). Adjuvants typically enhance the immunogenicity of an immunogen but are not necessarily immunogenic in and of themselves. Adjuvants may act by retaining the immunogen locally

15 near the site of administration to produce a depot effect facilitating a slow, sustained release of immunizing agent to cells of the immune system. Adjuvants can also attract cells of the immune system to an immunogen depot and stimulate such cells to elicit immune responses. As such, embodiments of this invention encompass compositions further comprising

20 adjuvants.

Desirable characteristics of ideal adjuvants include:

- 1) lack of toxicity;
- 2) ability to stimulate a long-lasting immune response;
- 3) simplicity of manufacture and stability in long-term storage;
- 25 4) ability to elicit both cellular and humoral responses to antigens administered by various routes, if required;
- 5) synergy with other adjuvants;
- 6) capability of selectively interacting with populations of antigen presenting cells (APC);

- 7) ability to specifically elicit appropriate TH1 or TH2 cell-specific immune responses; and
- 8) ability to selectively increase appropriate antibody isotype levels (for example, IgA) against antigens/immunogens.

5        However, many adjuvants are toxic and can cause undesirable side effects, thus making them unsuitable for use in humans and many animals. For example, some adjuvants may induce granulomas, acute and chronic inflammations (i.e. Freund's complete adjuvant (FCA)), cytolysis (i.e. saponins and pluronic polymers) and pyrogenicity, arthritis and anterior 10 uveitis (i.e. muramyl dipeptide (MDP) and lipopolysaccharide (LPS)). Indeed, only aluminum hydroxide and aluminum phosphate (collectively commonly referred to as alum) are routinely used as adjuvants in human and veterinary vaccines. The efficacy of alum in increasing antibody responses to diphtheria and tetanus toxoids is well established. 15 Notwithstanding, it does have limitations. For example, alum is ineffective for influenza vaccination and inconsistently elicits a cell mediated immune response with other immunogens. The antibodies elicited by alum-adjuvanted antigens are mainly of the IgG1 isotype in the mouse, which may not be optimal for protection in vaccination contexts.

20       Adjuvants may be characterized as "intrinsic" or "extrinsic". Intrinsic adjuvants (such as lipopolysaccharides) are integral and normal components of agents which in themselves are used as vaccines (i.e. killed or attenuated bacteria). Extrinsic adjuvants are typically nonintegral immunomodulators generally linked to antigens in a noncovalent manner, 25 and are formulated to enhance the host immune response.

      In embodiments of the invention, adjuvants can be at least one member chosen from the group consisting of cytokines, lymphokines, and co-stimulatory molecules. Examples include (but are not limited to)

interleukin 2, interleukin 12, interleukin 6, interferon gamma, tumor necrosis factor alpha, GM-CSF, B7.1, B7.2, ICAM-1, LFA-3, and CD72. Particular embodiments specifically encompass the use of GM-CSF as an adjuvant (as taught, for example, in US Patent Nos. 5679356, 5904920, 5637483, 5 5759535, 5254534, European Patent Application EP 211684, and published PCT document WO 97/28816 - all of which are herein incorporated by reference).

A variety of potent extrinsic adjuvants have been described. These include (but are not limited to) saponins complexed to membrane protein 10 antigens (immune stimulating complexes), pluronic polymers with mineral oil, killed mycobacteria and mineral oil, Freund's complete adjuvant, bacterial products such as muramyl dipeptide (MDP) and lipopolysaccharide (LPS), as well as lipid A, and liposomes.

The use of saponins *per se* as adjuvants is also well known 15 (Lacaille-Dubois, M. and Wagner, H. (1996) *Phytomedicine* 2:363). For example, Quil A (derived from the bark of the South American tree Quillaja Saponaria Molina) and fractions thereof has been extensively described (i.e. U.S. Patent No. 5057540; Kensil, C.R. (1996) *Crit Rev Ther Drug Carrier Syst.* 12:1; and European Patent EP 362279). The haemolytic saponins 20 QS21 and QS17 (HPLC purified fractions of Quil A) have been described as potent systemic adjuvants (U.S. Patent No. 5057540; European Patent EP 362279). Also described in these references is the use of QS7 (a non-haemolytic fraction of Quil-A) which acts as a potent adjuvant for systemic vaccines. Use of QS21 is further described in Kensil et al. ((1991) *J. 25 Immunol.* 146:431). Combinations of QS21 and polysorbate or cyclodextrin are also known (WO 9910008). Particulate adjuvant systems comprising fractions of Quil A (such as QS21 and QS7) are described in WO 9633739 and WO 9611711.

Another preferred adjuvant/immunostimulant is an immunostimulatory oligonucleotide containing unmethylated CpG dinucleotides ("CpG"). CpG is an abbreviation for cytosine-guanosine dinucleotide motifs present in DNA. CpG is known in the art as being an adjuvant when administered by both systemic and mucosal routes (WO 9602555; European Patent EP 468520; Davies et al. (1998) *J. Immunol.* 160:87; McCluskie and Davis (1998) *J. Immunol.* 161:4463). In a number of studies, synthetic oligonucleotides derived from BCG gene sequences have also been shown to be capable of inducing immunostimulatory effects (both in vitro and in vivo; Krieg, (1995) *Nature* 374:546). Detailed analyses of immunostimulatory oligonucleotide sequences has demonstrated that the CG motif must be in a certain sequence context, and that such sequences are common in bacterial DNA but are rare in vertebrate DNA. (For example, the immunostimulatory sequence is often: purine, purine, C, G, pyrimidine, pyrimidine, wherein the CG motif is not methylated; however other unmethylated CpG sequences are known to be immunostimulatory and as such may also be used in the present invention.) As will be evident to one of normal skill in the art, said CG motifs/sequences can be incorporated into nucleic acids of the invention *per se*, or reside on distinct nucleic acids.

A variety of other adjuvants are taught in the art, and as such are encompassed by embodiments of this invention. U.S. Patent No. 4,855,283 granted to Lockhoff et al. (incorporated herein by reference) teaches glycolipid analogues and their use as adjuvants. These include N-glycosylamides, N-glycosylureas and N-glycosylcarbamates, each of which is substituted in the sugar residue by an amino acid, as immuno-modulators or adjuvants. Furthermore, Lockhoff et al. ((1991) *Chem. Int. Ed. Engl.* 30:1611) have reported that N-glycolipid analogs displaying structural similarities to the naturally-occurring glycolipids (such as

glycophospholipids and glycoglycerolipids) are also capable of eliciting strong immune responses in both herpes simplex virus vaccine and pseudorabies virus vaccine.

U.S. Patent No. 4,258,029 granted to Moloney (incorporated herein by reference) teaches that octadecyl tyrosine hydrochloride (OTH) functions as an adjuvant when complexed with tetanus toxoid and formalin inactivated type I, II and III poliomyelitis virus vaccine. Nixon-George et al. ((1990) *J. Immunol.* 14:4798) have also reported that octadecyl esters of aromatic amino acids complexed with a recombinant hepatitis B surface antigen enhanced the host immune responses against hepatitis B virus.

Adjuvant compounds may also be chosen from the polymers of acrylic or methacrylic acid and the copolymers of maleic anhydride and alkenyl derivative. Adjuvant compounds are the polymers of acrylic or methacrylic acid which are cross-linked, especially with polyalkenyl ethers of sugars or polyalcohols. These compounds are known by the term carbomer (Pharneuropa Vol. 8, No. 2, June 1996). Preferably, a solution of adjuvant according to the invention, especially of carbomer, is prepared in distilled water, preferably in the presence of sodium chloride, the solution obtained being at acidic pH. This stock solution is diluted by adding it to the desired quantity (for obtaining the desired final concentration), or a substantial part thereof, of water charged with NaCl, preferably physiological saline (NaCL 9 g/l) all at once in several portions with concomitant or subsequent neutralization (pH 7.3 to 7.4), preferably with NaOH. This solution at physiological pH will be used as it is for mixing with the immunizing agent; said mixture being amenable to storage in the freeze-dried, liquid or frozen form.

Persons skilled in the art can also refer to U.S. Patent No. 2,909,462 (incorporated herein by reference) which describes adjuvants

encompassing acrylic polymers cross-linked with a polyhydroxylated compound having at least 3 hydroxyl groups (preferably not more than 8), the hydrogen atoms of the at least three hydroxyls being replaced by unsaturated aliphatic radicals having at least 2 carbon atoms. The 5 preferred radicals are those containing from 2 to 4 carbon atoms (e.g. vinyls, allyls and other ethylenically unsaturated groups). The unsaturated radicals may themselves contain other substituents, such as methyl. The products sold under the name Carbopol (BF Goodrich, Ohio, USA) are particularly appropriate. They are cross-linked with allyl sucrose or with allyl 10 pentaerythritol. Among them, there may be mentioned Carbopol (for example, 974P, 934P and 971P). Among the copolymers of maleic anhydride and alkenyl derivative, the copolymers EMA (Monsanto; which are copolymers of maleic anhydride and ethylene, linear or cross-linked, (for example cross-linked with divinyl ether)) are preferred. Reference may be 15 made to J. Fields et al. ((1960) *Nature* 186: 778) for a further description of these chemicals (incorporated (herein by reference)).

In further aspects of this invention, adjuvants useful for parenteral administration of immunizing agent include aluminum compounds (such as aluminum hydroxide, aluminum phosphate, and aluminum hydroxy 20 phosphate; but might also be a salt of calcium, iron or zinc, or may be an insoluble suspension of acylated tyrosine, or acylated sugars, cationically or anionically derivatised polysaccharides, or polyphosphazenes). The antigen can be precipitated with, or adsorbed onto, the aluminum compound according to standard protocols well known to those skilled in 25 the art.

Other adjuvants encompassed by embodiments of this invention include lipid A (in particular 3-de-O-acylated monophosphoryl lipid A (3D-MPL). 3D-MPL is a well known adjuvant manufactured by Ribi

Immunochem, Montana. It is often supplied chemically as a mixture of 3-de-O-acylated monophosphoryl lipid A with 4, 5, or 6 acylated chains. It can be prepared by the methods taught in GB 2122204B. A preferred form of 3D-MPL is in the form of a particulate formulation having a particle size less than 0.2 µm in diameter (European Patent EP 689454).

Adjuvants for mucosal immunization may include bacterial toxins (e.g., the cholera toxin (CT), the *E. coli* heat-labile toxin (LT), the *Clostridium difficile* toxin A and the pertussis toxin (PT), or combinations, subunits, toxoids, or mutants thereof). For example, a purified preparation of native cholera toxin subunit B (CTB) can be of use. Fragments, homologs, derivatives, and fusion to any of these toxins are also suitable, provided that they retain adjuvant activity. A mutant having reduced toxicity may be used. Mutants have been described (e.g., in WO 95/17211 (Arg-7-Lys CT mutant), WO 96/6627 (Arg-192-Gly LT mutant), and WO 95/34323 (Arg-9-Lys and Glu-129-Gly PT mutant)). Additional LT mutants include, for example Ser-63-Lys, Ala-69-Gly, Glu-110-Asp, and Glu-112-Asp mutants. Other adjuvants (such as a bacterial monophosphoryl lipid A (MPLA)) of various sources (e.g., *E. coli*, *Salmonella minnesota*, *Salmonella typhimurium*, or *Shigella flexneri*) can also be used in the mucosal administration of immunizing agents.

Adjuvants useful for both mucosal and parenteral immunization include polyphosphazene (for example, WO 95/2415), DC-chol (3 b-(N-(N',N'-dimethyl aminomethane)-carbamoyl) cholesterol (for example, U.S. Patent No. 5,283,185 and WO 96/14831) and QS-21 (for example, WO 88/9336).

Adjuvants/immunostimulants as described herein may be formulated together with carriers, such as for example liposomes, oil in water emulsions, and/or metallic salts including aluminum salts (such as

aluminum hydroxide). For example, 3D-MPL may be formulated with aluminum hydroxide (as discussed in EP 689454) or oil in water emulsions (as discussed in WO 9517210); QS21 may be advantageously formulated with cholesterol containing liposomes (as discussed in WO 9633739), in oil 5 water emulsions (as discussed in WO 9517210) or alum (as discussed in WO 9815287). When formulated into vaccines, immunostimulatory oligonucleotides (i.e. CpGs) are generally administered in free solution together with free antigen (as discussed in WO 9602555; McCluskie and Davis (1998) *Supra*), covalently conjugated to an antigen (as discussed in 10 WO 9816247), or formulated with a carrier such as aluminum hydroxide or alum (as discussed in Davies et al. *Supra*; Brazolot-Millan et al (1998) *Proc. Natl. Acad. Sci.* 95:15553).

Combinations of adjuvants/immunostimulants are also within the scope of this invention. For example, a combination of a monophosphoryl 15 lipid A and a saponin derivative (as described in WO 9400153, WO 9517210, WO 9633739, WO 9856414, WO 9912565, WO 9911214) can be used, or more particularly the combination of QS21 and 3D-MPL (as described in WO 9400153). A combination of an immunostimulatory oligonucleotide and a saponin (such as QS21), or a combination of 20 monophosphoryl lipid A (preferably 3D-MPL) in combination with an aluminum salt also form a potent adjuvant for use in the present invention.

The following non-limiting example is illustrative of the present invention:

#### EXAMPLES

25 **Example 1**

This example compares the intranodal injection with subcutaneous injection of a representative tumor antigen (modified gp100).

## Methods and Experimental Design

### Test System

Cynomolgus monkeys (Macaca fascicularis) purpose bred animals.

Supplier: Siconbrec "Simian Conservation Breeding & Research Center

5 Inc.", Fema Building, 44 Gil Puyat Avenue Makati, Metro Manila, Philippines.

Number of animals in the study: 12 (6 males and 6 females).

Age at initiation of treatment: 26 to 38 months.

- Body weight range at initiation of treatment (day -1):

- males: 1.73 to 2.34 kg

10 ▪ females: 1.71 to 2.65 kg.

### Animal Husbandry

- Housing: one air-conditioned room;

- temperature: 19 to 25°C (target range),

- relative humidity: >40%

15 ▪ air changes: minimum 8 air changes per hour,

- lighting cycle: 12 hours light (artificial)/12 hours dark.

- Caging: animals were housed singly in stainless steel mesh cages (approximately 540 x 810 x 760 mm).

- Diet: expanded complete commercial primate diet (Mazuri diet, Special

20 Diet Services Ltd., Witham, Essex, CM8, 3AD, Great Britain) analyzed for chemical and bacterial contaminants.

Quantity distributed: 100g diet/animal/day.

In addition, animals received fruit daily (apple or banana)

Animals were fasted for at least 16 hours before blood sampling for clinical

25 laboratory investigations and before necropsy.

- Water: drinking water *ad libitum* (via bottles).

- Contaminants: no known contaminants were present in diet or water at levels which might have interfered with achieving the objective of the study.

**Pre-Treatment Procedures**

- Animal health procedure: all animals received a clinical examination for ill-health on arrival and a veterinary clinical examination during the acclimatization period.
- 5 ▪ Acclimatization period: at least 3 weeks between animal arrival and start of treatment.

**Experimental Design**

- Allocation to treatment groups was performed during the acclimatization period using a random allocation procedure based on body weight classes.
- 10 ▪ Animals were assigned to the treatment groups shown in Table 1. The dose levels administered were shown in Table 2.

**Administration of the Test/Control Articles****Group 1 and 2 Animals**

- Method of administration: injection in the left inguinal lymph node.
- 15 Animals were lightly anaesthetized before each administration by an intramuscular injection of ketamine hydrochloride (Imalgene® 500 - Merial, Lyon, France). The same lymph node was injected on each occasion (left side). Each injection was followed by a local disinfection with iodine (Vétédine® - Vétoquinol, Lure, France).

**Group 3**

- Route: subcutaneous.
- Method of administration: bolus injection using a sterile syringe and needle introduced subcutaneously. Four injection sites were used followed by a local disinfection with iodine (Vétédine® - Vétoquinol, Lure, France).
- 25 Animals were also lightly anaesthetized before each administration by an intramuscular injection of ketamine hydrochloride (Imalgene® 500 - Merial, Lyon, France) in order to be under the same conditions as groups 1 and 2 animals.

Four injection sites in the dorsal cervical/interscapular regions were used as shown in Table 3.

▪ **ELISPOT Analysis**

An ELISPOT assay was used in order to assess the cell mediated immune response generated in the monkeys in the various treatment groups. In particular, an ELISPOT IFN $\gamma$  assay was used in order to measure IFN $\gamma$  production from T lymphocytes obtained from the monkeys in response to gp100 antigens.

**10 Materials and Methods**

Plates: MILLIPORE Multiscreen HA plate / MAHA S45.10 (96 wells).

Capture antibodies: MABTECH monoclonal anti-IFN $\gamma$  antibodies/G-Z4 1 mg/mL.

Detection antibodies: MABTECH monoclonal anti-IFN $\gamma$  antibodies/7-B6-1-15 biotin 1 mg/mL.

Enzyme: SIGMA, Extravidin-PA conjugate/E2636

Substrate: BIORAD, NBT/BCIP - Alkaline phosphatase conjugate substrate kit/ref: 170-64 32.

**Coating**

20 Place 100  $\mu$ L per well of capture antibodies at 1  $\mu$ g/mL diluted at 1/1000 in carbonate bicarbonate buffer 0.1M pH 9.6 into the multiwell plate. Incubate overnight at 4°C. Wash 4 times in 1X PBS.

**Saturation**

Place 200  $\mu$ L per well of RPMI supplemented with 10% FCS, non essential amino acids, pyruvate, Hepes buffer and Peni-Strepto. Incubate 2 hours at 37°C.

**Test**

Cells from the immunized animals are tested against (a) medium alone; (b) pooled peptides at a concentration of 1 mg/mL; and (c) a non specific

stimulus (PMA-Iono). The pooled peptides used in this Example to stimulate IFN- $\gamma$  production were derived from gp100 and are illustrated in Tables 4 to 7. The final volume of each sample is 200  $\mu$ L. Incubate 20 hours at 37°C.

- 5 Wash 4 times in 1X PBS and 0.05% Tween 20.  
**Detection**

Place 100  $\mu$ L per well of detection antibodies at 1  $\mu$ g/mL diluted in 1/1000 1X PBS, 1% BSA and 0.05% Tween 20. Incubate 2 hours at room temperature. Wash 4 times in 1X PBS and 0.05% Tween 20.

- 10 **Reaction**

Place 100  $\mu$ L per well of Extravidin-PA conjugate diluted 1/6000 in 1X PBS, 1% BSA and 0.05% Tween 20. Incubate 45 minutes at room temperature.

Wash 4 times in 1X PBS and 0.05% Tween 20.

**Substrate Addition**

- 15 Place 100  $\mu$ L per well of substrate previously prepared. For example, for 1 plate, prepare: 9.6 mL of distilled water, 0.4 mL of 25X buffer, 0.1 mL of solution A (NBT) and 0.1 mL of solution B (BCIP). Incubate 30-45 minutes at room temperature. Wash in distilled water. Dry and transfer to a plastic film. The number of spots are counted using a Zeiss image analyzer. Each  
20 spot corresponds to an individual IFN- $\gamma$  secreting T cell.

### **Results**

The animals that tested positive on the ELISPOT analysis are shown in Figures 1-4. Overall, the results demonstrate that of the animals tested, 2  
25 out of 2 (i.e. 100%) of the animals that received the intranodal administration of the gp100 antigen, and 2 out of 4 (i.e. 50%) of the animals that received the subcutaneous administration of the gp100 antigen had a positive cell mediated immune response.

### ELISA Analysis

The ELISA was performed utilizing standard methodology known in the art. Briefly, the human gp100 ("hgp100"; produced in Baculovirus) was diluted in 5 coating buffer (carbonate-bicarbonate, pH9.6) and added to 96 wells at 0.5ug/well. Plates were placed at 4°C overnight. Plates were then washed and blocking buffer (phosphate buffered saline/0.5% Tween 20/1.0% BSA, pH7.2) was added for 2 hours at 37°C. The plates were then washed and the sera was diluted in dilution buffer (phosphate buffered saline/0.5 % 10 Tween 20/ 0.1 BSA, pH7.2). For this study, monkey sera was diluted to 1:800 and "7" serial 3 fold dilutions were done for each sample tested. The human sera controls were diluted to 1:50 in dilution buffer and "7" serial 2 fold dilutions were performed. Each dilution was done in duplicate. The plates were incubated a further 2 hours at 37°C. The plates were washed 15 and the horse radish peroxidase (HRP)-conjugated anti-human secondary antibody (anti-human Ig whole antibody from sheep (Amersham Life Science, NA933)) diluted 1:100 in dilution buffer was added to the wells and incubated for 1 hour at 37°C. The plates were washed and OPD (o-phenylenediamine dihydrochloride) substrate with H<sub>2</sub>O<sub>2</sub> in substrate buffer 20 (50mM phosphate/25mM citrate, pH 7.2) was added to the wells. For a kinetics ELISA, the plate was read repeatedly (2 minute intervals for 15 minutes) unstopped (without "stop" buffer). Plates were read at 450nm.

### Results

25 The results of the above experiment are presented in Table 8 and in Figure 5. The animals of group 2 received intranodal injections of ALVAC(2)-gp100(mod) followed by boosts with the modified gp100 peptides 209(2M) and 290(9V); the animals in group 3 received a subcutaneous

injection of the ALVAC(2) construct followed by peptide boosts; the animals in group 1 received intranodal injections of saline as a control.

As can be seen from Figure 5, intranodal injection of the antigens induced a humoral response that was much greater than when the antigen 5 was injected subcutaneously.

In summary, the results of this Example demonstrate that intranodal injection of a tumor antigen induces both a humoral and cell mediated response that is much greater than when the tumor antigen is injected by the conventional subcutaneous route of administration.

10 While the present invention has been described with reference to what are presently considered to be the preferred examples, it is to be understood that the invention is not limited to the disclosed examples. To the contrary, the invention is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the 15 appended claims.

All publications, patents and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety.

TABLE 1

| <b>Group Number</b> | <b>Route of administration</b> | <b>Treatment days and compound administered</b>   | <b>Number of Animals</b> |
|---------------------|--------------------------------|---|--------------------------|
| 1                   | Intranodal                     | Saline (NaCl 0.9%): days 28, 42, 56<br>Then 70, 71, 72, 73, 74<br>Then 84, 85, 86, 87 and 88                            | 4                        |
| 2                   | Intranodal                     | <u>ALVAC(2) - gp100 mod:</u> days 28, 42, 56<br>*mgp100 peptides: days 70, 71, 72, 73, 74<br>Then 84, 85, 86, 87 and 88 | 4                        |
| 3                   | Subcutaneous                   | Saline (NaCl 0.9%): day 1<br><u>ALVAC(2) - gp100 mod:</u> days 28, 42, 56<br>*mgp100 peptides: days 70 and 84           | 4                        |

\*209(2M)-IMDQVPFSY; 290(9V) YLEPGPVTV

- 5    ▪ Group 1 animals (control) received the control article (saline for injection (NaCl 0.9%)).  
     ▪ Group 3 animals received the control article (saline for injection (NaCl 0.9%)) on day 1 only.

36  
TABLE 2

| <b>Group Number</b> | <b>Dose level</b>   | <b>Dose volume (ml/administration)</b> |
|---------------------|---|--|
| 1                   | Saline (NaCl 0.9%): 0   | 0.250                                  |
| 2                   | Dose: $0.25 \times 10^{7.4}$ CCID 50<br>ALVAC (2) - gp100 mod: $0.25 \times 10^{7.4}$ CCID50<br><br>Dose: 200 µg (Total) of peptides IMDQVPFSY (209(2M)),<br>and YLEPGPVTV (290(9V)) (100µg each) | 0.250<br><br>0.2                       |
| 3                   | Saline (NaCl 0.9%)<br><br>ALVAC(2) - gp100 mod: $0.25 \times 10^{7.4}$ CCID 50<br><br>Dose: 200 µg (Total) of peptides IMDQVPFSY (209(2M)),<br>and YLEPGPVTV (290(9V)) (100µg each)               | 0.250<br><br>0.250<br><br>0.2          |

37  
TABLE 3

| Days     | Sites used  |
|----------|-------------|
| 1 and 28 | lower left  |
| 42       | upper left  |
| 56       | upper right |
| 70       | lower left  |
| 84       | lower right |

**TABLE 4**

Peptide Pool #1

| Peptide | Sequence         | SEQ.ID.NO.   |
|---------|------------------|--------------|
| 1329    | HLAVIGALLAVGATK  | SEQ.ID.NO.3  |
| 1330    | GALLAVGATKVPRNQ  | SEQ.ID.NO.4  |
| 1331    | VGATKVPRNQDWLGV  | SEQ.ID.NO.5  |
| 1332    | VPRNQDWLGVSRLQR  | SEQ.ID.NO.6  |
| 1333    | DWLGVSRQLRTKAWN  | SEQ.ID.NO.7  |
| 1334    | SRQLRTKAWNRLQYP  | SEQ.ID.NO.8  |
| 1335    | TKAWNRLQLYPEWTEA | SEQ.ID.NO.9  |
| 1336    | RQLYPEWTEAQRLDC  | SEQ.ID.NO.10 |
| 1337    | EWTEAQRLDCWRGGQ  | SEQ.ID.NO.11 |
| 1338    | QRLLDCWRGGQVSLKV | SEQ.ID.NO.12 |
| 1339    | WRGGQVSLKVSNDGP  | SEQ.ID.NO.13 |
| 1340    | VSLKVSNDGPTLIGA  | SEQ.ID.NO.14 |
| 1344    | IALNFPGSQKVLPDG  | SEQ.ID.NO.15 |
| 1345    | PGSQKVLPDGQVIWV  | SEQ.ID.NO.16 |
| 1346    | VLPDGQVIWVNNTII  | SEQ.ID.NO.17 |
| 1347    | QVIWVNNTIINGSQV  | SEQ.ID.NO.18 |
| 1348    | NNTIINGSQVWGGQP  | SEQ.ID.NO.19 |
| 1349    | NGSQVWGGQPVYPQE  | SEQ.ID.NO.20 |
| 1350    | WGGQPVYPQETDDAC  | SEQ.ID.NO.21 |
| 1351    | VYPQETDDACIFPDG  | SEQ.ID.NO.22 |
| 1352    | TDDACIFPDGGPCPS  | SEQ.ID.NO.23 |
| 1353    | IFPDGGPCPSGSWSQ  | SEQ.ID.NO.24 |
| 1355    | GSWSQKRSFVYVWKT  | SEQ.ID.NO.25 |
| 1356    | KRSFVYVWKTWQYQW  | SEQ.ID.NO.26 |
| 1357    | YVWKTWQYWQVLGG   | SEQ.ID.NO.27 |
| 1358    | WGQYWQVLGGPVSGL  | SEQ.ID.NO.28 |
| 1359    | QVLGGPVSGLSIGTG  | SEQ.ID.NO.29 |

39  
TABLE 5

Peptide Pool #2

| Peptide | Sequence         | SEQ.ID.NO.   |
|---------|------------------|--------------|
| 1360    | PVSGLSIGTGRAMLG  | SEQ.ID.NO.30 |
| 1361    | SIGTGRAMLGTHTME  | SEQ.ID.NO.31 |
| 1362    | RAMLGTHTMEVTVYH  | SEQ.ID.NO.32 |
| 1363    | THTMEVTVYHRRGSR  | SEQ.ID.NO.33 |
| 1364    | VTVYHRRGSRSYVPL  | SEQ.ID.NO.34 |
| 1365    | RRGSRSYVPLAHSSS  | SEQ.ID.NO.35 |
| 1366    | SYVPLAHSSSAFTIT  | SEQ.ID.NO.36 |
| 1368    | AFTITDQVPFSVSVS  | SEQ.ID.NO.37 |
| 1369    | DQVPPFSVSSQLRAL  | SEQ.ID.NO.38 |
| 1370    | SVSVSQLRALDGGNK  | SEQ.ID.NO.39 |
| 1372    | DGGNKHFLRNQPLTF  | SEQ.ID.NO.40 |
| 1373    | HFLRNQPLTFALQLH  | SEQ.ID.NO.41 |
| 1374    | QPLTFALQLHDPSGY  | SEQ.ID.NO.42 |
| 1375    | ALQLHDPSGYLAEAD  | SEQ.ID.NO.43 |
| 1379    | DFGDSSGTLISRALV  | SEQ.ID.NO.44 |
| 1380    | STGLISRALKVVTHTY | SEQ.ID.NO.45 |
| 1381    | SRALVVTHTYLEPGP  | SEQ.ID.NO.46 |
| 1382    | VTHTYLEPGPVTAQV  | SEQ.ID.NO.47 |
| 1383    | LEPGPVTAQVVLQAA  | SEQ.ID.NO.48 |
| 1384    | VTAQVVLQAAIPLTS  | SEQ.ID.NO.49 |
| 1385    | VLQAAIPLTSCGSSP  | SEQ.ID.NO.50 |
| 1386    | IPLTSCGSSPVGTT   | SEQ.ID.NO.51 |
| 1388    | VPGTTDGHRPTAEAP  | SEQ.ID.NO.52 |
| 1389    | DGHRPTAEAPNTTAG  | SEQ.ID.NO.53 |
| 1390    | TAEAPNTTAGQVPTT  | SEQ.ID.NO.54 |
| 1392    | QVPTTEVVGTTPGQA  | SEQ.ID.NO.55 |
| 1393    | EVVGTTPGQAPTAEP  | SEQ.ID.NO.56 |

40  
**TABLE 6**

Peptide Pool #3

| Peptide | Sequence         | SEQ.ID.NO.   |
|---------|------------------|--------------|
| 1394    | TPGQAPTAEPSGTTS  | SEQ.ID.NO.57 |
| 1395    | PTAEPSGTTSVQVPT  | SEQ.ID.NO.58 |
| 1396    | SGTTSVQVPTTEVIS  | SEQ.ID.NO.59 |
| 1397    | VQVPTTEVISTAPVQ  | SEQ.ID.NO.60 |
| 1398    | TEVISTAPVQMPTAEE | SEQ.ID.NO.61 |
| 1399    | TAPVQMPTAESTGMT  | SEQ.ID.NO.62 |
| 1400    | MPTAESTGMTPEKVP  | SEQ.ID.NO.63 |
| 1401    | STGMTPEKVPVSEVM  | SEQ.ID.NO.64 |
| 1402    | PEKVPVSEVMGTTLA  | SEQ.ID.NO.65 |
| 1403    | VSEVMGTTLAEMSTP  | SEQ.ID.NO.66 |
| 1404    | GTTLAEMSTPEATGM  | SEQ.ID.NO.67 |
| 1405    | EMSTPEATGMTPAEV  | SEQ.ID.NO.68 |
| 1408    | SIVVLSGTTAAQVTT  | SEQ.ID.NO.69 |
| 1409    | SGTTAAQVTTTEWVE  | SEQ.ID.NO.70 |
| 1410    | AQVTTTEWVETTARE  | SEQ.ID.NO.71 |
| 1411    | TEWVETTARELPIPE  | SEQ.ID.NO.72 |
| 1412    | TTARELPIPEPEGPD  | SEQ.ID.NO.73 |
| 1413    | LPIPEPEGPDASSIM  | SEQ.ID.NO.74 |
| 1414    | PEGPDASSIMSTESI  | SEQ.ID.NO.75 |
| 1415    | ASSIMSTESITGSLG  | SEQ.ID.NO.76 |
| 1416    | STESITGSLGPLLDG  | SEQ.ID.NO.77 |
| 1417    | TGSLGPLLDGTATLR  | SEQ.ID.NO.78 |
| 1418    | PLLDGTATRLVKRQ   | SEQ.ID.NO.79 |
| 1419    | TATRLVLKRQVPLDC  | SEQ.ID.NO.80 |
| 1420    | LVKRQVPLDCVLYRY  | SEQ.ID.NO.81 |
| 1421    | VPLDCVLYRYGSFSV  | SEQ.ID.NO.82 |
| 1422    | VLYRYGSFSVTLDIV  | SEQ.ID.NO.83 |

41  
**Table 7**

## Peptide Pool #4

| Peptide | Sequence         | SEQ.ID.NO.    |
|---------|------------------|---------------|
| 1424    | TLDIVQGIESAEILQ  | SEQ.ID.NO.84  |
| 1425    | QGIESAEILQAVPSG  | SEQ.ID.NO.85  |
| 1426    | AEILQAVPSGEGDAF  | SEQ.ID.NO.86  |
| 1427    | AVPSGEGDAFELTVS  | SEQ.ID.NO.87  |
| 1428    | EGDAFELTVSCQGGL  | SEQ.ID.NO.88  |
| 1429    | ELTVSCQGGLPKEAC  | SEQ.ID.NO.89  |
| 1430    | CQGGLPKEACMEISS  | SEQ.ID.NO.90  |
| 1431    | PKEACMEISSLPGCQP | SEQ.ID.NO.91  |
| 1432    | MEISSPGCQPPAQRL  | SEQ.ID.NO.92  |
| 1434    | PAQRLLCQPVLPSAC  | SEQ.ID.NO.93  |
| 1435    | CQPVLPSACQLVLH   | SEQ.ID.NO.94  |
| 1436    | PSPACQLVLHQILKG  | SEQ.ID.NO.95  |
| 1437    | QLVLHQILKGGSGTY  | SEQ.ID.NO.96  |
| 1441    | LADTNSLAVVSTQLI  | SEQ.ID.NO.97  |
| 1442    | SLAVVSTQLIMPGQE  | SEQ.ID.NO.98  |
| 1443    | STQLIMPGQEAGLGQ  | SEQ.ID.NO.99  |
| 1444    | MPGQEAGLGQVPLIV  | SEQ.ID.NO.100 |
| 1445    | AGLGQVPLIVGILLV  | SEQ.ID.NO.101 |
| 1448    | LMAVVVLASLIYRRRL | SEQ.ID.NO.102 |
| 1450    | YRRRLMKQDFSVPQL  | SEQ.ID.NO.103 |
| 1451    | MKQDFSVPQLPHSSS  | SEQ.ID.NO.104 |
| 1452    | SVPQLPHSSSHWLRL  | SEQ.ID.NO.105 |
| 1453    | PHSSSHWLRLPRIFC  | SEQ.ID.NO.106 |
| 1454    | HWLRLPRIFCSCPPIG | SEQ.ID.NO.107 |
| 1455    | PRIFCSCPPIGENSPL | SEQ.ID.NO.108 |

**TABLE 8**

| Monkey # | DAY (mOD/min) |    |    |    |
|----------|---------------|----|----|----|
|          | 0             | 57 | 68 | 96 |
| 1        | 3             | 5  | 2  | 2  |
| 2        | 4             | 6  | 12 | 10 |
| 3        | 7             | 6  | 10 | 8  |
| 4        | 7             | 6  | 8  | 8  |
| 5        | 5             | 9  | 20 | 15 |
| 6        | 11            | 8  | 10 | 12 |
| 7        | 11            | 23 | 51 | 30 |
| 8        | 7             | 30 | 70 | 22 |
| 9        | 1             | 7  | 5  | 3  |
| 10       | 2             | 6  | 6  | 4  |
| 11       | 3             | 7  | 14 | 8  |
| 12       | 6             | 9  | 15 | 6  |

**We claim:**

1. A method for inducing an immune response in an animal to a tumor antigen comprising administering an effective amount of a tumor antigen or a nucleic acid sequence encoding a tumor antigen to a lymphatic site in the animal.
2. A method according to claim 1 wherein the tumor antigen is selected from the group consisting of CEA, gp100, the MAGE family of proteins, DAGE, GAGE, RAGE, NY-ESO 1, Melan-A/MART 1, TRP-1, TRP-2, tyrosinase, HER-2/neu, MUC-1, p53, KSA, PSA, PSMA, and fragments and modified versions thereof.
- 15 3. A method according to claim 1 or 2 wherein the lymphatic site is a lymph node.
4. A method according to any one of claims 1 to 3 wherein the nucleic acid is selected from the group consisting of viral nucleic acid, bacterial DNA, plasmid DNA, naked/free DNA, and RNA.
- 20 5. A method according to claim 4 wherein the viral nucleic acid is selected from the group consisting of adenoviral, alphaviral and poxviral nucleic acid.
- 25 6. A method according to claim 5 wherein the poxviral nucleic acid is selected from the group consisting of avipox, orthopox and suipox nucleic acid.
- 30 7. A method according to claim 5 wherein the poxviral nucleic acid is selected from the group consisting of vaccinia, fowl pox, canarypox and swinepox nucleic acid.

8. A method according to claim 5 wherein the poxviral nucleic acid is selected from the group consisting of MVA, NYVAC, TROVAC, and ALVAC nucleic acid.

5

9. A method according to any one of claims 1 to 8 wherein the nucleic acid is contained in a vector.

10. A method according to claim 9 wherein the vector is a recombinant virus or bacteria.

11. A method according to claim 10 wherein the recombinant virus is selected from the group consisting of adenovirus, alphavirus and poxvirus.

15

12. A method according to claim 11 wherein the poxvirus is selected from the group consisting of avipox, orthopox and suipox.

20

13. A method according to claim 11 wherein the poxvirus is selected from the group consisting of vaccinia, fowlpox, canarypox and swinepox.

14. A method according to claim 11 wherein the poxvirus is selected from the group consisting of MVA, NYVAC, TROVAC, and ALVAC.


25

15. A method according to any one of claims 1 to 8 wherein the nucleic acid is contained in a cell.

16. A method according to any one of claims 1 to 14 wherein the tumor antigen or nucleic acid coding therefor is contained in a vaccine.

- 45
17. A method according to any one of claims 1 to 16 wherein the tumor antigen is gp100, CEA or a fragment or modified version of gp100 or CEA.
- 5 18. A method according to claim 17 wherein the modified gp100 comprises the sequence IMDQVPFSY (SEQ ID NO: 1) and/or YLEPGPVTV (SEQ ID NO:2).
- 10 19. A method according to claim 17 wherein the modified CEA comprises the sequence shown in Figure 8 (SEQ ID NO:112) and/or YLSGADLNL (SEQ ID NO:113).


1/11

**FIGURE 1****Monkey #6 (Intranodal Administration)**


2/11

FIGURE 2

## Monkey #7 (Intranodal Administration)




3/11


**FIGURE 3****Monkey # 11 (Subcutaneous Administration)****Spots/1E6 Cells**

4/11

FIGURE 4  
Monkey #10 (Subcutaneous Administration)



5/11

**FIGURE 5**

6/11

**FIGURE 6**

ATGG ATCTGGTGCT AAAAAGATGC CTTCTTCATT TGGCTGTGAT  
AGGTGCTTTG CTGGCTGTGG GGGCTACAAA AGTACCCAGA AACCAGGACT GGCTTGGTGT  
CTCAAGCAA CTCAGAACCA AAGCCTGGAA CAGGCAGCTG TATCCAGAGT GGACAGAAC  
CCAGAGACTT GACTGCTGGA GAGGTGGTCA AGTGTCCCTC AAGGTCAAGTA ATGATGGGCC  
TACACTGATT GGTGCAAATG CCTCCTTCTC TATTGCCTTG AACTTCCCTG GAAGCAAAA  
GGTATTGCCA GATGGGCAGG TTATCTGGGT CAACAATACC ATCATCAATG GGAGCCAGGT  
GTGGGGAGGA CAGCCAGTGT ATCCCCAGGA AACTGACGAT GCCTGCATCT TCCCTGATGG  
TGGACCTTGC CCATCTGGCT CTTGGTCTCA GAAGAGAACG TTTGTTTATG TCTGGAAGAC  
CTGGGGCCAA TACTGGCAAG TTCTAGGGGG CCCAGTGTCT GGCTGAGCA TTGGGACAGG  
CAGGGCAATG CTGGGCACAC ACACGATGGA AGTGAUTGTC TACCATGCC GGGGATCCCG  
GAGCTATGTG CCTCTTGCTC ATTCCAGCTC AGCCTTCACC ATTATGGACC AGGTGCCTT  
CTCCGTGAGC GTGTCCCAGT TGCGGGCCTT GGATGGAGGG ACAAAGCACT TCCTGAGAAA  
TCAGCCTCTG ACCTTTGCC TCCAGCTCCA TGACCCCCAGT GGCTATCTGG CTGAAGCTGA  
CCTCTCCTAC ACCTGGGACT TTGGAGACAG TAGTGGAAAC CTGATCTCTC GGGCACTTGT  
GGTCACTCAT ACTTACCTGG AGCCTGGCCC AGTCACTGTT CAGGTGGTCC TGCAGGCTGC  
CATTCCCTCTC ACCTCCTGTG GCTCCTCCCC AGTTCCAGGC ACCACAGATG GGCACAGGCC  
AACTGCAGAG GCCCCTAACCA CCACAGCTGG CCAAGTGCCT ACTACAGAAG TTGTGGGTAC  
TACACCTGGT CAGGCGCCAA CTGCAGAGCC CTCTGGAACC ACATCTGTGC AGGTGCCAAC  
CACTGAAGTC ATAAGCACTG CACCTGTGCA GATGCCAACT GCAGAGAGCA CAGGTATGAC  
ACCTGAGAAG GTGCCAGTT CAGAGGTCAAT GGGTACCCACA CTGGCAGAGA TGTCAACTCC  
AGAGGCTACA GGTATGACAC CTGCAGAGGT ATCAATTGTG GTGCTTCTG GAACCACAGC  
TGCACAGGTA ACAACTACAG AGTGGGTGGA GACCACAGCT AGAGAGCTAC CTATCCCTGA  
GCCTGAAGGT CCAGATGCCA GCTCAATCAT GTCTACGGAA AGTATTACAG GTTCCCTGGG  
CCCCCTGCTG GATGGTACAG CCACCTTAAG GCTGGTGAAG AGACAAGTCC CCCTGGATTG  
TGTTCCTGTAT CGATATGGTT CCTTTCCGT CACCTGGAC ATTGTCCAGG GTATTGAAAG  
TGCCGAGATC CTGCAGGGCTG TGCCGTCCGG TGAGGGGGAT GCATTTGAGC TGACTGTGTC  
CTGCCAAGGC GGGCTGCCA AGGAAGCCTG CATGGAGATC TCATGCCAG GGTGCCAGCC  
CCCTGCCAG CGGCTGTGCC AGCCTGTGCT ACCCAGCCCA GCCTGCCAGC TGGTTCTGCA  
CCAGATACTG AAGGGTGGCT CGGGGACATA CTGCCTCAAT GTGTCTCTGG CTGATACCAA  
CAGCCTGGCA GTGGTCAGCA CCCAGCTTAT CATGCCCTGGT CAAGAACGAG GCCTTGGCA  
GGTTCCGCTG ATCGTGGCA TCTTGCTGGT GTTGATGGCT GTGGTCCTTG CATCTCTGAT  
ATATAGGCAGC AGACTTATGA AGCAAGAGACTT CTCCGTACCC CAGTTGCCAC ATAGCAGCAG  
TCACTGGCTG CGTCTACCCC GCATCTTCTG CTCTTGTCCC ATTGGTGAGA ACAGCCCCCT  
CCTCAGTGGG CAGCAGGTCT GA

7/11

## FIGURE 7

Met Asp Leu Val Leu Lys Arg Cys Leu Leu His Leu Ala Val Ile Gly  
   1               5               10               15  
 Ala Leu Leu Ala Val Gly Ala Thr Lys Val Pro Arg Asn Gln Asp Trp  
   20              25              30  
 Leu Gly Val Ser Arg Gln Leu Arg Thr Lys Ala Trp Asn Arg Gln Leu  
   35              40              45  
 Tyr Pro Glu Trp Thr Glu Ala Gln Arg Leu Asp Cys Trp Arg Gly Gly  
   50              55              60  
 Gln Val Ser Leu Lys Val Ser Asn Asp Gly Pro Thr Leu Ile Gly Ala  
   65              70              75              80  
 Asn Ala Ser Phe Ser Ile Ala Leu Asn Phe Pro Gly Ser Gln Lys Val  
   85              90              95  
 Leu Pro Asp Gly Gln Val Ile Trp Val Asn Asn Thr Ile Ile Asn Gly  
   100             105             110  
 Ser Gln Val Trp Gly Gly Gln Pro Val Tyr Pro Gln Glu Thr Asp Asp  
   115             120             125  
 Ala Cys Ile Phe Pro Asp Gly Gly Pro Cys Pro Ser Gly Ser Trp Ser  
   130             135             140  
 Gln Lys Arg Ser Phe Val Tyr Val Trp Lys Thr Trp Gly Gln Tyr Trp  
   145             150             155             160  
 Gln Val Leu Gly Gly Pro Val Ser Gly Leu Ser Ile Gly Thr Gly Arg  
   165             170             175  
 Ala Met Leu Gly Thr His Thr Met Glu Val Thr Val Tyr His Arg Arg  
   180             185             190  
 Gly Ser Arg Ser Tyr Val Pro Leu Ala His Ser Ser Ser Ala Phe Thr  
   195             200             205  
 Ile Met Asp Gln Val Pro Phe Ser Val Ser Val Ser Gln Leu Arg Ala  
   210             215             220  
 Leu Asp Gly Gly Asn Lys His Phe Leu Arg Asn Gln Pro Leu Thr Phe  
   225             230             235             240  
 Ala Leu Gln Leu His Asp Pro Ser Gly Tyr Leu Ala Glu Ala Asp Leu  
   245             250             255  
 Ser Tyr Thr Trp Asp Phe Gly Asp Ser Ser Gly Thr Leu Ile Ser Arg  
   260             265             270  
 Ala Leu Val Val Thr His Thr Tyr Leu Glu Pro Gly Pro Val Thr Val  
   275             280             285  
 Gln Val Val Leu Gln Ala Ala Ile Pro Leu Thr Ser Cys Gly Ser Ser  
   290             295             300  
 Pro Val Pro Gly Thr Thr Asp Gly His Arg Pro Thr Ala Glu Ala Pro  
   305             310             315             320  
 Asn Thr Thr Ala Gly Gln Val Pro Thr Thr Glu Val Val Gly Thr Thr  
   325             330             335  
 Pro Gly Gln Ala Pro Thr Ala Glu Pro Ser Gly Thr Thr Ser Val Gln  
   340             345             350  
 Val Pro Thr Thr Glu Val Ile Ser Thr Ala Pro Val Gln Met Pro Thr  
   355             360             365

8/11

**FIGURE 7 (CONT'D)**

Ala Glu Ser Thr Gly Met Thr Pro Glu Lys Val Pro Val Ser Glu Val  
     370                         375                         380  
 Met Gly Thr Thr Leu Ala Glu Met Ser Thr Pro Glu Ala Thr Gly Met  
     385                         390                         395                         400  
 Thr Pro Ala Glu Val Ser Ile Val Val Leu Ser Gly Thr Thr Ala Ala  
     405                         410                         415  
 Gln Val Thr Thr Glu Trp Val Glu Thr Thr Ala Arg Glu Leu Pro  
     420                         425                         430  
 Ile Pro Glu Pro Glu Gly Pro Asp Ala Ser Ser Ile Met Ser Thr Glu  
     435                         440                         445  
 Ser Ile Thr Gly Ser Leu Gly Pro Leu Leu Asp Gly Thr Ala Thr Leu  
     450                         455                         460  
 Arg Leu Val Lys Arg Gln Val Pro Leu Asp Cys Val Leu Tyr Arg Tyr  
     465                         470                         475                         480  
 Gly Ser Phe Ser Val Thr Leu Asp Ile Val Gln Gly Ile Glu Ser Ala  
     485                         490                         495  
 Glu Ile Leu Gln Ala Val Pro Ser Gly Glu Gly Asp Ala Phe Glu Leu  
     500                         505                         510  
 Thr Val Ser Cys Gln Gly Leu Pro Lys Glu Ala Cys Met Glu Ile  
     515                         520                         525  
 Ser Ser Pro Gly Cys Gln Pro Pro Ala Gln Arg Leu Cys Gln Pro Val  
     530                         535                         540  
 Leu Pro Ser Pro Ala Cys Gln Leu Val Leu His Gln Ile Leu Lys Gly  
     545                         550                         555                         560  
 Gly Ser Gly Thr Tyr Cys Leu Asn Val Ser Leu Ala Asp Thr Asn Ser  
     565                         570                         575  
 Leu Ala Val Val Ser Thr Gln Leu Ile Met Pro Gly Gln Glu Ala Gly  
     580                         585                         590  
 Leu Gly Gln Val Pro Leu Ile Val Gly Ile Leu Leu Val Leu Met Ala  
     595                         600                         605  
 Val Val Leu Ala Ser Leu Ile Tyr Arg Arg Arg Leu Met Lys Gln Asp  
     610                         615                         620  
 Phe Ser Val Pro Gln Leu Pro His Ser Ser Ser His Trp Leu Arg Leu  
     625                         630                         635                         640  
 Pro Arg Ile Phe Cys Ser Cys Pro Ile Gly Glu Asn Ser Pro Leu Leu  
     645                         650                         655  
 Ser Gly Gln Gln Val  
     660

9/11

## FIGURE 8

ATGGAGTCCTCCCTCGGCCCTCCCCACAGATGGTGCATCCCCTGGCAGAGGCTCTGCTC  
 1 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 60  
 TACCTCAGAGGGAGCCGGGGAGGGGTGCTACACGTAGGGGACCGTCTCGAGGACGAG  
 a M E S P S A P P H R W C I P W Q R L L L -  
 ACAGCCTCACTTCAACCTTCTGAAACCCGCCACCAGTCCAAGCTCACTATTGAATCC  
 61 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 120  
 TGTCGGAGTGAAGATTGGAAGACCTGGCGGGTGGTGACGTTGAGTGATAACTTAGG  
 a T A S L L T F W N P P T T A K L T I E S -  
 ACGCCGTTCAATGTCGAGAGGGAGGGGTGCTTCACTTGTCCACAATCTGCCAG  
 121 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 180  
 TGCAGCAAGTTACAGCGTCTCCCTCCAGAAGATGAACAGGTGTTAGACGGGTC  
 a T P F N V A E G K E V L L L V H N L P Q -  
 CATCTTTGGCTACAGCTGGTACAAGGTGAAAGAGTGGATGGCAACCGTCAAATTATA  
 181 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 240  
 GTAGAAAAACCGATGTCGACCATGTTCACTTCTCACCTACCGTTGGCAGTTAATAT  
 a H L F G Y S W Y K G E R V D G N R Q I I -  
 GGATATGTAATAGAACCTAACAGCTACCCAGGGCCCGCATACAGTGGTCGAGAGATA  
 241 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 300  
 CCTATACATTATCCTTGAGTTGTTGATGGGTCGGCGTATGTCACCAAGCTCTAT  
 a G Y V I G T Q Q A T P G P A Y S G R E I -  
 ATATACCCCAATGCATCCCTGCTGATCCAGAACATCATCCAGAACATGACACAGGATTCTAC  
 301 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 360  
 TATATGGGTTACGTAGGGACGACTAGGTCTTGTAGTAGGTCTTACTGTGTCCTAACAGAT  
 a I Y P N A S L L I Q N I I Q N D T G F Y -  
 ACCCTACACGTCAAAAGTCAGATCTTGTAATGAAAGAACACTGGCCAGTCCGGTA  
 361 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 420  
 TGGATGTGCAGTATTCAGTCTAGAACACTTACTTCTCGTTGACCGGTCAAGGCCAT  
 a T L H V I K S D L V N E E A T G Q F R V -  
 TACCCGGAGCTGCCAAGCCCTCATCTCAGAACAACTCCAAACCCGTGGAGGACAAG  
 421 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 480  
 ATGGGCTCGACGGGTCGGAGGTAGAGGTGTTGAGGTTGGCACCTCCTGTC  
 a Y P E L P K P S I S S N N S K P V E D K -  
 GATGCTGTGGCCTTCACCTGTGAAACCTGAGACTCAGGACGCAACCTACCTGTGGTGGTA  
 481 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 540  
 CTACGACACCGGAAGTGGACACTTGGACTCTGAGTCCTCGTTGGATGGACACCACCAT  
 a D A V A F T C E P E T Q D A T Y L W W V -  
 AACAAATCAGAGGCCCTCCGGTCAGTCCCAGGCTGCAGCTGTCAATGGCAACAGGACCC  
 541 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 600  
 TTGTTAGTCTCGGAGGGCCAGTCAGGGTCCGACGTCGACAGGTTACCGTTGTCTGGAG  
 a N N Q S L P V S P R L Q L S N G N R T L -  
 ACTCTATTCAATGTCACAAGAAATGACACAGCAAGCTACAAATGTGAAACCCAGAACCCA  
 601 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 660  
 TGAGATAAGTTACAGTGTCTTACTGTGTCGTTGATGTTACACTTGGTCTGGGT  
 a T L F N V T R N D T A S Y K C E T Q N P -  
 GTGAGTGCCAGGCGCAGTGTTCAGTCATCCTGAATGTCCTCTATGGCCGGATGCC  
 661 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 720  
 CACTCACGGTCCCGTCACTAAGTCAGTAGGACTTACAGGAGATACCGGGCTACGGGG  
 a V S A R R S D S V I L N V L Y G P D A P -

10/11

## FIGURE 8 (CONT'D)

ACCATTTCCCCTCAAACACATCTTACAGATCAGGGGAAAATCTGAACCTCTCCTGCCAC  
 721 -----+-----+-----+-----+-----+-----+-----+-----+ 780  
 TGGTAAAGGGAGATTGTGAGAATGTCTAGTCCCCTTAGACTTGGAGAGGACGGTG  
  
 a T I S P L N T S Y R S G E N L N L S C H -  
  
 GCAGCCTCTAACCCACCTGCACAGTACTCTGGTTGTCAATGGGACTTTCCAGCAATCC  
 781 -----+-----+-----+-----+-----+-----+-----+-----+ 840  
 CGTCGGAGATTGGTGGACGTGTCAAGAACCTGAAAGGTGCGTTAGG  
  
 a A A S N P P A Q Y S W F V N G T F Q Q S -  
  
 ACCCAAGAGCTTTATCCCCAACATCACTGTGAATAATAGTGGATCCTATACGTGCCAA  
 841 -----+-----+-----+-----+-----+-----+-----+-----+ 900  
 TGGGTTCTCGAGAAATAGGGTTGTAGTACACTTATTACACCTAGGATATGCACGGTT  
  
 a T Q E L F I P N I T V N N S G S Y T C Q -  
  
 GCCCATRACTCAGACACTGGCCTCAATAGGACCACAGTCAGCACGATCACAGTCTATGAG  
 901 -----+-----+-----+-----+-----+-----+-----+-----+ 960  
 CGGGTATTGAGTCTGTGACCGGAGTTATCCTGGTGTCACTGCTAGTGTCAAGATACTC  
  
 a A H N S D T G L N R T T V T T I T V Y E -  
  
 CCACCCAAACCCCTTCATCACCAAGCAACAACCTCAACCCGGAGGATGAGGATGCTGTA  
 961 -----+-----+-----+-----+-----+-----+-----+-----+ 1020  
 GGTGGGTTGGAAAGTAGTGGTCGTTGAGGTTGGGACACCTCCTACTCCTACGACAT  
  
 a P P K P F I T S N N S N P V E D E D A V -  
  
 GCCTTAACCTGTGAACCTGAGATTCAAGAACACAACCTACCTGTGGTGGTAAATAATCAG  
 1021 -----+-----+-----+-----+-----+-----+-----+-----+ 1080  
 CGGAATTGGACACTTGGACTCTAAGTCTGTGTTGGATGGACACCCACCTTATTAGTC  
  
 a A L T C E P E I Q N T T Y L W W V N N Q -  
  
 AGCCTCCGGTCAGTCCCAGGCTGCAGCTGCCAATGACAACAGGACCTCACTCTACTC  
 1081 -----+-----+-----+-----+-----+-----+-----+-----+ 1140  
 TCGGAGGGCCAGTCAGGGTCCAGCTGACAGGTTACTGTTGTCTGGAGTGAGATGAG  
  
 a S L P V S P R L Q L S N D N R T L T L L -  
  
 AGTGTACAAGGAATGATGTAGGACCCATGAGTGTGGAATCCAGAACGAATTAAGTGT  
 1141 -----+-----+-----+-----+-----+-----+-----+-----+ 1200  
 TCACAGTGTCCCTACTACATCCTGGATACTCACACCTAGGTCTGCTTAATTACAA  
  
 a S V T R N D V G P Y E C G I Q N E L S V -  
  
 GACCACAGCGACCCAGTCATCCTGAATGTCCTCTATGGCCAGACGACCCACCATTC  
 1201 -----+-----+-----+-----+-----+-----+-----+-----+ 1260  
 CTGGTGTGCTGGTCAGTAGGACTTACAGGAGATAACCGGGTCTGCTGGGTGGTAAAGG  
  
 a D H S D P V I L N V L Y G P D D P T I S -  
  
 CCCTCATACACCTATTACCGTCCAGGGTGAACCTCAGCCTCTCCTGCCATGCAGCCCT  
 1261 -----+-----+-----+-----+-----+-----+-----+-----+ 1320  
 GGGAGTATGTGGATAATGGCAGGTCCCACCTGGACTCGAGAGGACGGTACGTGGAGA  
  
 a P S Y T Y Y R P G V N L S L S C H A A S -  
  
 AACCCACCTGCACAGTATTCTGGCTGATTGATGGGAACATCCAGAACACACACAAGAG  
 1321 -----+-----+-----+-----+-----+-----+-----+-----+ 1380  
 TTGGGTGGACGTGTCAAGAACCGACTAACCTACCTGTAGGTGCTGGTGTGTTCTC  
  
 a N P P A Q Y S W L I D G N I Q Q H T Q E -  
  
 CTCTTATCTCAAACATCACTGAGAAGAACAGCGGACTCTATACCTGCCAGGCCAATAAC  
 1381 -----+-----+-----+-----+-----+-----+-----+-----+ 1440  
 GAGAAATAGAGGTGAGTGTACTCTCTGCGCTGAGATATGGACGGTCCGGTTATTG  
  
 a L F I S N I T E K N S G L Y T C Q A N N -  
 SUBSTITUTIONS -----

11/11

## FIGURE 8 (CONT'D)

1441 TCAGCCAGTGGCCACAGCAGGACTACAGTCAGACAATCACAGTCTCTGGAGCTGCC  
1500 ACTCGGTACCGGTGTCGTCTGATGTCAGTTCTGTTAGTGTCAAGAGACGCCCGACGGG

a S A S G H S R T T V K T I T V S A E L P -  
1501 AAGCCCTCCATCTCCAGCAACAACTCCAACCCGTGGAGGACAAGGATGCTGTGGCCTTC  
1560 TTCGGGAGGTAGAGGTGTTGAGGTTGGCACCTCTGTTCTACGACACCGGAAG

a K P S I S S N N S K P V E D K D A V A F -  
1561 ACCTGTGAACCTGAGGCTCAGAACACAACCTACCTGTGGTGGTAAATGGTCAGAGCCTC  
1620 TGGACACTTGGACTCCGAGTCTGTGGATGGACACCACCCATTACAGTCTCGGAG

a T C E P E A Q N T T Y L W W V N G Q S L -  
1621 CCAGTCAGTCCCAGGCTGCAGCTGTCATGGCAACAGGACCCCTCACTCTATTCAATGTC  
1680 GGTCAGTCAGGGTCCGACGTCGACAGGTTACCGTTGTGGAGTGGATAAGTTACAG

a P V S P R L Q L S N G N R T L T L F N V -  
1681 ACAAGAAATGACGCAAGAGCCTATGTATGGAATCCAGAACCTCAGTGAGTGCAAACCGC  
1740 TGTCTTTACTGCGTTCTCGGATACATACACCTTAGGTCTTGAGTCACGTGGTGGCG

a T R N D A R A Y V C G I Q N S V S A N R -  
1741 AGTGACCCAGTCACCCCTGGATGTCCTCTATGGGCCGGACACCCCCCATTTCCCCCCC  
1800 TCACTGGGTCACTGGGACCTACAGGAGATAACCCGGCTGTGGGGTAGTAAAGGGGGGT

a S D P V T L D V L Y G P D T P I I S P P -  
1801 GACTCGTCTTACCTTCGGGAGCGGACCTCAACCTCTCTGCCACTCGGCCTTAACCCA  
1860 CTGAGCAGAATGAAAGCCCTCGCTGGAGTTGGAGAGGACGGTGAGCCGGAGATTGGGT

a D S S Y L S G A D L N L S C H S A S N P -  
1861 TCCCCGCAGTATCTTGGGTATCAATGGGATACCGCAGCAACACACACAAGTTCTCTT  
1920 AGGGCGTCATAAGAACCGCATAGTTACCTATGGCGTGTGTGTTCAAGAGAAA

a S P Q Y S W R I N G I P Q Q H T Q V L F -  
1921 ATCGCCAAATCAGCCAAATAATAACGGGACCTATGCCCTTTGTCTCTAACCTGGCT  
1980 TAGCGGTTTAGTCGGTTATTATGCCCTGGATACGGACAAAACAGAGATTGAACCGA

a I A K I T P N N N G T Y A C F V S N L A -  
1981 ACTGGCCGCAATAATTCCATAGTCAGAGCATCACAGTCTCTGCATCTGGAACTTCCCT  
2040 TGACCGGCCTTAAAGGTATCAGTTCTCGTAGTGTCAAGAGACGTAGACCTTGAAGAGGA

a T G R N N S I V K S I T V S A S G T S P -  
2041 GGTCTCTCAGCTGGGCCACTGTCGGCATCATGATTGGAGTGCTGGTGGGGTTGCTCTG  
2100 CCAGAGAGTCGACCCCGGTGACAGCCGTAGTACTAACCTCACGACCAACCCAAACGAGAC

a G L S A G A T V G I M I G V L V G V A L -  
2101 ATATAG ←  
2106 TATATC  
a I \* ←

## INTERNATIONAL SEARCH REPORT

--- ational Application No

. /CA 00/01253

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61K39/00 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

MEDLINE, CANCERLIT, LIFESCIENCES, EMBASE, SCISEARCH, EPO-Internal, BIOSIS, WPI Data, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|------------|--|-----------------------|
| X          | WO 97 47271 A (GUO YAJUN)<br>18 December 1997 (1997-12-18)<br>page 23, line 14 -page 24, line 22<br>----   | 1-3, 15,<br>16        |
| X          | RAO V S ET AL: "PARTIAL CHARACTERIZATION<br>OF TWO SUBPOPULATIONS OF T-4 CELLS INDUCED<br>BY ACTIVE SPECIFIC INTRALYMPHATIC<br>IMMUNOTHERAPY IN MELANOMA PATIENTS"<br>PROCEEDINGS AMERICAN ASSOCIATION FOR<br>CANCER RESEARCH ANNUAL MEETING,<br>vol. 27, 1986, page 325 XP000990377<br>ISSN: 0197-016X<br>the whole document<br>----<br>-/- | 1, 2, 16              |

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

16 March 2001

26/03/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Covone, M

## INTERNATIONAL SEARCH REPORT

| INT   | Patent Application No  |                       |
|---|--|-----------------------|
| PCT/CA 00/01253   |  |                       |
| <b>C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT</b> |  |                       |
| Category *  | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
| A   | <p>MACKENSEN ANDREAS ET AL: "Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells."</p> <p>CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 48, no. 2-3, May 1999 (1999-05), pages 118-122, XP000990346</p> <p>ISSN: 0340-7004</p> <p>the whole document</p> <p>---</p> | 1-19                  |
| A   | <p>IRVINE KARI R ET AL: "Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens."</p> <p>CANCER RESEARCH, vol. 59, no. 11, 1 June 1999 (1999-06-01), pages 2536-2540, XP002161590</p> <p>ISSN: 0008-5472</p> <p>the whole document</p> <p>-----</p>   | 1-19                  |

**INTERNATIONAL SEARCH REPORT**

II. Information on patent family members

National Application No

PCT/CA 00/01253

| Patent document cited in search report | Publication date | Patent family member(s) |            | Publication date |
|--|------------------|-------------------------|------------|------------------|
| WO 9747271                             | A 18-12-1997     | AU                      | 727955 B   | 04-01-2001       |
|  |                  | AU                      | 4228397 A  | 07-01-1998       |
|  |                  | CA                      | 2258082 A  | 18-12-1997       |
|  |                  | CN                      | 1221349 A  | 30-06-1999       |
|  |                  | EP                      | 0956046 A  | 17-11-1999       |
|  |                  | JP                      | 11514666 T | 14-12-1999       |